UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2022

Commission File Number: 001-37384

GALAPAGOS NV
(Translation of registrant's name into English)

Generaal De Wittelaan L11 A3
2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

First Half-Year 2022 Results

On August 4, 2022, the Registrant announced its unaudited first half-year results for 2022, which are further described in an H1 2022 report.

Exhibit	Description
99.1	Press Release dated August 4, 2022
99.2	H1 Report 2022

The information contained in this Report on Form 6-K, including the exhibits, except for the quotes of Dr. Paul Stoffels and Mr. Bart Filius, contained in Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-231765, 333-249416 and 333-260500).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GALAPAGOS NV
(Registrant)
/s/ Marie-Théodora Vandewiele
Marie-Théodora Vandewiele
Company Secretary

Date: August 8, 2022

First key steps in pipeline rebuild and strong commercial progress in H1 2022

- **First half-year 2022 financial results:**
  - **Jyseleca® net sales reached €35.4 million**
  - **Group revenues of €274.0 million**
  - **Operating loss of €97.5 million**
  - **Cash and current financial investments of €4.4 billion on 30 June 2022**
- **Increased 2022 guidance for Jyseleca from €65-75 million to €75-85 million**
- **Combined acquisitions of CellPoint and AboundBio in all-cash transactions positions company in CAR-T therapy space**

Webcast presentation tomorrow, 5 August 2022, at 14.00 CET / 8 AM ET, www.glpg.com,

Mechelen, Belgium; 4 August 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced its first half-year 2022 financial results, a year-to-date business update and its outlook for the remainder of 2022. The results are further detailed in the H1 2022 financial report available on the financial reports section of the website.

"This quarter, we took a first key step in our strategic transformation by entering the field of oncology with the acquisitions of CellPoint and AboundBio. The combined transactions offer the potential for a paradigm shift in CAR-T[1] therapy through CellPoint's breakthrough, decentralized point-of-care supply model, developed in a global strategic collaboration with Lonza, and AboundBio's cutting-edge fully human antibody-based capabilities to design next-generation CAR-Ts. Patient enrolment in the ongoing Phase 1/2a trials in rrNHL and rrCLL[2] is progressing well, and we expect topline results in the first half of next year. Our near-term goal is to bring three additional differentiated, next-generation CAR-T candidates in the clinic over the next three years," said Dr. Paul Stoffels[3], CEO and chairman of the board of directors of Galapagos. "We strongly believe that we are taking the right steps in our transformation to accelerate value creation, and we look forward to presenting an in-depth update on our strategy later this year."

"Our Jyseleca franchise is performing very well with robust sales momentum, supported by the regulatory approvals in ulcerative colitis (UC) in Great Britain and Japan earlier this year. The adoption of Jyseleca is strong across Europe with reimbursement for rheumatoid arthritis (RA) in 15 and for UC in 6 countries," added Bart Filius, President, COO and CFO of Galapagos. "Following the acquisitions of CellPoint and AboundBio, we expect that second half operating expenses will increase by approximately €30 million. Therefore, we revised our cash burn[i] guidance of €450-€490 million for the full year 2022 to €480-€520 million. As a result of the strong Jyseleca performance, we increase our full-year net sales guidance of €65-€75 million to €75-€85 million."

1 Chimeric antigen receptor T-cell
2 rrNHL: relapsed/refractory non-Hodgkin Lymphoma, rrCLL: relapsed/refractory Chronic Lymphocytic Leukemia
3 Acting via Stoffels IMC BV

Year-to-date operational overview

Commercial & regulatory progress:

- Strong adoption across Europe with reimbursement for RA in 15 countries and for UC in 6 countries
- Sobi, our distribution and commercialization partner in Eastern and Central Europe, Portugal, Greece, and the Baltic countries, launched Jyseleca in RA in the Czech Republic and Portugal, resulting in €2 million milestone payments to Galapagos in H1
- Filed a type II variation for the label update for Jyseleca based on data from the MANTA and MANTA-RAy studies
- At the EULAR[4] 2022 European Congress of Rheumatology, Galapagos hosted several expert sessions and presented 11 abstracts, further establishing us as a key player in RA
- Article 20 pharmacovigilance procedure ongoing by the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), investigating the safety data of all JAK inhibitors for the treatment of certain chronic inflammatory disorders

Pipeline update:

- Decided to move forward with GLPG3667 (TYK2 inhibitor) in dermatomyositis with the aim to start a Phase 2 study before year-end
- Discontinued development of 4 early-stage programs as part of ongoing scientific and strategic exercise: GLPG3121, a local release formulation JAK1/TYK2 inhibitor with potential in inflammatory diseases; GLPG0555, a JAK1 inhibitor evaluated in osteoarthritis; GLPG4586, a compound with undisclosed mode of action directed toward fibrosis; and GLPG4716, a chitinase inhibitor directed toward idiopathic pulmonary fibrosis

Corporate update:

- Entered the field of oncology through the combined acquisitions of CellPoint and AboundBio in all-cash transactions
- Received a transparency notification from FMR LLC in Q2 indicating that its shareholding in Galapagos increased and crossed the 5% threshold, to 5.04% of the current outstanding Galapagos shares
- Raised €3.6 million through the exercise of subscription rights
- Created new subscription rights plans, offering all Galapagos employees the opportunity to participate
- All proposed resolutions regarding the extraordinary and annual shareholders' meetings were adopted by Galapagos' shareholders on 26 April 2022

[4] European Alliance of Associations for Rheumatology

First half-year 2022 financial highlights (unaudited)
(€ millions, except basic & diluted income/loss per share)

	30 June 2022 group total	30 June 2021 group total	Variance
Product net sales	35.4	0.5	34.9
Collaboration revenues	238.6	253.2	(14.6)
Total net revenues	**274.0**	**253.7**	**20.3**
Cost of sales	(5.5)	(0.1)	(5.4)
R&D expenditure	(249.5)	(268.8)	19.3
G&A[ii] and S&M[iii] expenses	(134.0)	(105.8)	(28.2)
Other operating income	17.6	23.6	(5.9)
Operating loss	**(97.5)**	**(97.6)**	**0.1**
Net financial result	67.7	19.9	47.8
Income taxes	(2.5)	0.5	(3.0)
Net loss from continuing operations	**(32.3)**	**(77.2)**	**44.9**
Net profit from discontinued operations	—	22.2	(22.2)
Net loss of the period	**(32.3)**	**(55.0)**	**22.7**
Basic and diluted loss per share (€)	(0.49)	(0.84)	
Basic and diluted loss per share from continuing operations (€)	(0.49)	(1.18)	
Current financial investments and cash and cash equivalents	**4,429.0**	**5,006.6**	

H1 2022 financial results

We reported product net sales of Jyseleca in Europe for the first six months of 2022 amounting to €35.4 million (€0.5 million in the first six months of 2021). Our counterparties for the sales of Jyseleca were mainly hospitals and wholesalers located in Belgium, the Netherlands, France, Italy, Spain, Germany, Great Britain, Ireland, Austria, Norway, Sweden and Finland.

Cost of sales related to Jyseleca net sales in the first six months of 2022 amounted to €5.5 million.

Collaboration revenues amounted to €238.6 million for the first six months of 2022, compared to €253.2 million for the first six months of 2021.

Revenues recognized related to the collaboration agreement with Gilead for the filgotinib development were €115.3 million in the first six months of 2022 compared to €136.1 million for the same period last year. This decrease was due to a lower increase in the percentage of completion, partly offset by a higher revenue recognition of milestone payments, strongly influenced by the milestone achieved related to the regulatory approval in Japan for UC in the first half-year of 2022. The revenue recognition related to the exclusive access rights for Gilead to our drug discovery platform amounted to €114.9 million for the first six months of 2022 (€115.7 million for the same period last year).

We have recognized royalty income from Gilead for Jyseleca for €6.3 million in the first six months of 2022 (compared to €1.4 million in the same period last year) of which €3.6 million royalties on milestone income for UC approval in Japan.

Additionally, we recorded milestones of €2.0 million triggered by the first sale of Jyseleca in the Czech Republic and Portugal by our distribution and commercialization partner Sobi, in the first half-year of 2022.

Our deferred income balance on 30 June 2022 includes €1.6 billion allocated to our drug discovery platform that is recognized linearly over the remaining period of our 10-year collaboration, and €0.5 billion allocated to the filgotinib development that is recognized over time until the end of the development period.

Our R&D expenditure in the first six months of 2022 amounted to €249.5 million, compared to €268.8 million for the first six months of 2021. This decrease was primarily explained by a decrease in subcontracting costs from €139.2 million in the first six months of 2021 to €104.1 million in the first six months of 2022, primarily due to the winding down of the ziritaxestat (IPF) program and reduced spend on our Toledo (SIKi) and TYK2 programs. This was partly offset by cost increases for our filgotinib program, on a six month basis compared to the same period in 2021. Personnel costs decreased from €94.2 million in the first half of 2021 to €86.0 million for the same period this year mainly due to a lower number of FTEs as well as lower costs for our subscription right plans. Depreciation and impairment amounted to €32.6 million for the first six months of 2022 (€8.1 million for the same period last year). This increase was primarily due to an impairment of €26.7 million of previously capitalized upfront fees related to our collaboration with Molecure on the dual chitinase inhibitor OATD-01 (GLPG4716). As part of an ongoing strategic exercise to renew and accelerate our portfolio, we decided to return all rights to OATD-01 to Molecure.

Our G&A and S&M expenses amounted to €134.0 million in the first six months of 2022, compared to €105.8 million in the first six months of 2021. This increase was primarily due to the termination of our 50/50 filgotinib co-commercialization cost sharing agreement with Gilead for filgotinib in 2022. The cost increase was also explained by an increase in personnel costs for the first six months of 2022 compared to the same period last year explained by an increase in the commercial work force driven by the commercial launch of filgotinib in Europe.

Other operating income (€17.6 million vs €23.6 million for the same period last year) decreased, mainly driven by lower grant and R&D incentives income.

Net financial income in the first six months of 2022 amounted to €67.7 million, compared to net financial income of €19.9 million for the first six months of 2021. Net financial income in the first six months of 2022 was primarily attributable to €57.4 million of unrealized currency exchange gains on our cash and cash equivalents and current financial investments at amortized cost in U.S. dollars, and to €11.8 million of positive changes in (fair) value of current financial investments. The financial expenses also contained the effect of discounting our long term deferred income of €3.8 million.

We realized a net loss from continuing operations of €32.3 million for the first six months of 2022, compared to a net loss of €77.2 million for the first six months of 2021.

The net profit from discontinued operations for the six months ended 30 June 2021 consisted of the gain on the sale of Fidelta, our fee-for-services business, for €22.2 million.

We reported a group net loss for the first six months of 2022 of €32.3 million, compared to a group net loss of €55.0 million for the first six months of 2021.

Cash position

Current financial investments and cash and cash equivalents totaled €4,429.0 million on 30 June 2022, as compared to €4,703.2 million on 31 December 2021.

Total net decrease in cash and cash equivalents and current financial investments amounted to €274.2 million during the first six months of 2022, compared to a net decrease of €162.7 million during the first six months of 2021. This net decrease was composed of (i) €217.1 million of operational cash burn, (ii) offset by €3.6 million of cash proceeds from capital and share premium increase from exercise of subscription rights in the first six months of 2022, (iii) €11.8 million positive changes in (fair) value of current financial investments and €60.4 million of mainly positive exchange rate differences, and (iv) the cash out from the acquisitions of CellPoint and AboundBio, net of cash acquired, of €132.9 million.

Acquisitions of CellPoint and AboundBio

The preliminary accounting of the acquisitions of CellPoint and AboundBio are included in our H1 2022 condensed consolidated financial statements. To date, we have performed a preliminary fair value analysis of the business combinations. We expect the provisional amount of goodwill to change significantly upon the completion of the purchase price allocation, resulting from the valuation of the different assets and liabilities acquired.

Outlook 2022

Financial guidance:
Following the acquisitions of CellPoint and AboundBio, we revised our cash burn guidance for full year 2022 from €450-€490 million to €480-€520 million. Additionally, we increased our anticipated net sales guidance for Jyseleca from €65-€75 million to between €75 and €85 million.

Expected regulatory events:
We anticipate a Committee for Medicinal Products for Human Use (CHMP) opinion on the type II variation for the Jyseleca label, based on the data from the MANTA and MANTA-RAy studies around year-end. We also expect reimbursement decisions in most key European markets in UC and anticipate that Sobi will further progress with reimbursement discussions in RA and UC in Eastern and Central Europe, Greece, and the Baltic countries. As part of the ongoing article 20 pharmacovigilance procedure on all JAK inhibitors approved in Europe, we expect a CHMP opinion by the end of the year, followed by an adoption by the European Commission shortly afterwards.

Anticipated R&D milestones:
Patient enrolment in the Phase 1/2a trials in rrNHL and rrCLL is progressing well and we anticipate that additional clinical sites will be active by year-end. We are on track to report topline results of both trials in the first half of next year.
We plan to progress TYK2 inhibitor GLPG3667 into a Phase 2 program in dermatomyositis with first patients potentially recruited around year-end.

We continue to explore additional business development opportunities to further leverage our internal capabilities and renew our portfolio, and we look forward to presenting an in-depth update on our corporate strategy later this year.

First half-year 2022 financial report

Galapagos' financial report for the first six months ended 30 June 2022, including details of the unaudited consolidated results, is accessible on the financial reports section of our website.

Conference call and webcast presentation

Management will host a conference call and webcast presentation followed by Q&A tomorrow 5 August 2022, at 14:00 CET / 8 AM ET. To participate in the conference call, please register in advance using this link. Upon registration, the dial-in numbers will be provided. The conference call can be accessed 10 minutes prior to the start time by using the conference access information provided in the e-mail received at the point of registering, or by selecting the *call me* feature.

The live webcast can be accessed on the investors section of the Galapagos website, and a replay will be made available shortly after the close of the call.

Financial calendar 2022

3 November 2022	Third quarter 2022 results	(webcast 4 November 2022)
23 February 2023	Full year 2022 results	(webcast 24 February 2023)

About Galapagos

Galapagos is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 3 programs in inflammation, oncology, fibrosis, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is approved and available in the European Union (including Norway), Great Britain and Japan. For additional information, please visit www.glpg.com or follow us on LinkedIn or Twitter.

Except for filgotinib's approval as Jyseleca® for the treatment of rheumatoid arthritis and ulcerative colitis by the European Commission, Great Britain's Medicines and Healthcare products Regulatory Agency and Japanese Ministry of Health, Labour and Welfare, our drug candidates are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority.

Jyseleca® is a trademark of Galapagos NV and Gilead Sciences, Inc. or its related companies.

Contact

Investors:

Sofie Van Gijsel
Head of Investor Relations
+1 781 296 1143

Sandra Cauwenberghs
Director Investor Relations
+32 495 58 46 63
ir@glpg.com

Media:

Marieke Vermeersch
Head of Corporate Communication
+32 479 490 603
media@glpg.com

Forward-looking statements

This press release includes forward-looking statements. These statements are often, but are not always, made through the use of words or phrases such as "believe," "anticipate," "expect," "intend," "plan," "seek," "estimate," "may," "will," "could," "would," "potential," "forward," "goal," "next," "stand to," "continue," "should," "encouraging," "aim," "explore," "further," as well as similar expressions. These statements include, but are not limited to, the information provide in the sections "Year-to-date operation overview" and "outlook 2022", the statements regarding the global R&D collaboration with Gilead and the amendment of our arrangement with Gilead for the commercialization and development of filgotinib, statements regarding the amount and timing of potential future milestones, opt-in and/or royalty payments, our R&D strategy, including progress on our fibrosis, inflammation, CAR-T portfolio, kidney disease and SIK platform, and potential changes of such ambitions, statements regarding our pipeline and complementary technology platforms driving future growth, the guidance from management (including guidance regarding the expected financial results, expected operational use of cash during financial year 2022 and our strategic and capital allocation priorities), statements regarding the acquisition of CellPoint and AboundBio (including statements regarding anticipated benefits of the acquisition and integration of CellPoint and AboundBio into our portfolio and strategic plans), statements regarding the expected timing, design and readouts of ongoing and planned clinical trials (or the discontinuation thereof), including recruitment for trials and topline results for our trials and studies in our portfolio, statements regarding the strategic re-evaluation, statements related to the EMA's safety review of JAK inhibitors used to treat certain inflammatory disorders, including filgotinib, initiated at the request of the European Commission (EC) under article 20 of Regulation (EC) No 726/2004, statements relating to interactions with regulatory authorities, the timing or likelihood of additional regulatory authorities' approval of marketing authorization for filgotinib for RA, UC or any other indication for filgotinib in Europe, Great Britain, Japan, and the U.S., such additional regulatory authorities requiring additional studies, the timing or likelihood of pricing and reimbursement interactions for filgotinib, statements relating to the build-up of our commercial organization, statements and expectations regarding commercial sales for filgotinib, and statements regarding our strategy, business plans and focus. We caution the reader that forward-looking statements are based on our management's current beliefs and expectations and are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause our actual results, financial condition and liquidity, performance or achievements of , or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to, the risk that our expectations regarding our 2022 revenues and financial results and our 2022 operating expenses may be incorrect (including because one or more of its assumptions underlying its expense expectations may not be realized), our expectations regarding its development programs may be incorrect, the inherent risks and uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including the risk that data from our ongoing and planned clinical research programs in RA, rrNHL, rrCLL, Crohn's disease, UC, IPF , other inflammatory indications, dermatomyositis, and kidney disease or any other indication or disease, may not support registration or further development of its product candidates due to safety or efficacy concerns or other reasons), risks related to the acquisition of CellPoint and AboundBio, including the risk that we may not achieve the anticipated benefits of the acquisition of CellPoint and AboundBio, the inherent risks and uncertainties associated with target discovery and validation and drug discovery and development activities, our reliance on collaborations with third parties (including our collaboration partner Gilead), the timing of and the risks related to the implementation of the transition of the European commercialization responsibility of filgotinib from Gilead to us, the risk that the transition will not be completed on the currently contemplated timeline or at all, including the transfer of the supply chain, and the risk that the transition will not have the currently expected results for our business and results of operations, estimating the commercial potential of our product candidates and our expectations regarding the costs and revenues associated with the transfer of European commercialization rights to filgotinib may be incorrect, the risk that we will not be able to continue to execute on our currently contemplated business plan and/or will revise our business plan, including the risk that our plans with respect to CAR-T may not be achieved on the currently anticipated timeline or at all, the risk that our projections and expectations regarding the costs and revenues with the commercialization rights may be inaccurate, the risk that we will be unable to successfully achieve the anticipated benefits from our leadership transition plan, the risk that we will encounter challenges retaining or attracting talent, risks related to disruption in our operations and ongoing studies (including our DIVERSITY 1 study) due to the conflict between Russia and Ukraine, the risks related to continued regulatory review of filgotinib following approval by relevant regulatory authorities and the EMA's safety review of JAK inhibitors used to treat certain inflammatory disorders, including the risk that the EMA and/or other regulatory authorities determine that additional non-clinical or clinical studies are required with respect to filgotinib, the risk that the EMA may require that the market authorization for filgotinib in the EU be amended, the risk that the EMA may impose JAK class-based warnings, the risk that the EMA's safety review may negatively impact acceptance of filgotinib by patients, the medical community and healthcare payors and the risks and uncertainties related to the impact of the COVID-19 pandemic. A further list and description of these risks, uncertainties and other risks can be found in our Securities and Exchange Commission (SEC) filings and reports, including in our most recent annual report on Form 20-F filed with the SEC and other filings and reports filed by us with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this document. We expressly disclaim any obligation to update any such forward-looking statements in this document to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

[i] The operational cash burn (or operational cash flow if this liquidity measure is positive) is equal to the increase or decrease in our cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus:

- the net proceeds, if any, from share capital and share premium increases included in the net cash flows generated from/used in (-) financing activities
- the net proceeds or cash used, if any, related to the acquisitions or disposals of businesses; the movement in restricted cash and movement in current financial investments, if any, the cash advances and loans given to third parties, if any, included in the net cash flows generated from/used in (-) investing activities
- the cash used for other liabilities related to the acquisition of businesses, if any, included in the net cash flows generated from/used in (-) operating activities.

This alternative liquidity measure is in our view an important metric for a biotech company in the development stage. The operational cash burn for the six months ended 30 June 2022 amounted to €217.1 million and can be reconciled to our cash flow statement by considering the decrease in cash and cash equivalents of €1,285.2 million, adjusted by (i) the cash proceeds from capital and share premium increase from the exercise of subscription rights by employees for €3.6 million, (ii) the net purchase of current financial investments amounting to €938.7 million, (iii) the cash out from acquisition of subsidiaries, net of cash acquired, of €132.9 million

[ii] General and administrative
[iii] Sales and marketing


Half-year financial report 2022
Foundation & Future
Galápagos
Pioneering for patients

Table of Contents

The Galapagos group

Letter to our shareholders 4
Potential external impact 8
Financial highlights 11
Risk factors 17
The Galapagos share 17
Related party transactions 18
Disclaimer and other information 19

Financial statements

Unaudited condensed consolidated interim financial statements 23
Notes 32

Other information

Glossary 48
Financial calendar 65
Colophon 66
Contact 67

The Galapagos group

An overview of Galapagos, its strategy and portfolio in H1 2022

Foundation & Future

Letter to our shareholders

Dear shareholders,

As we are writing the next chapter for our company, we embarked on a thorough strategic exercise to assess our current portfolio and combine internal and external innovation with the aim to accelerate transformational medicines to patients.

This quarter, we took a first key step in our strategic transformation by entering the field of oncology with the acquisitions of CellPoint and AboundBio. The combined transactions provide us with end-to-end capabilities in CAR-T[1] therapy and offer the potential for a paradigm shift in the space through CellPoint's breakthrough, decentralized point-of-care supply model, developed in a global strategic collaboration with Lonza, and AboundBio's cutting-edge fully human antibody-based capabilities to design next-generation CAR-Ts.

We warmly welcome the CellPoint and AboundBio teams to Galapagos, and we look forward to combining our unique capabilities to push the boundaries in oncology. Despite continued progress with current CAR-T cancer therapies, long lead times, costly central manufacturing and complex logistics continue to be limiting factors for large-scale capacity and broad patient access. The CellPoint novel point-of-care supply model, in or near the hospital, is designed to allow for efficient, 7-day delivery of CAR-T therapies with fresh cells, thereby offering the potential to significantly shorten time to treatment as compared to industry standards. It combines CellPoint's proprietary end-to-end xCellit workflow management and monitoring software with Lonza's Cocoon® system, a closed, automated manufacturing platform for cell and gene therapies. The regulatory authorities in Belgium, the Netherlands and Spain have approved the start of clinical studies with this novel supply model.

Two Phase 1/2a studies in rrNHL and rrCLL[2] with a clinically validated CD19 CAR-T target are ongoing and provide the opportunity for a rapid validation of the CellPoint CAR-T point-of-care supply model. Topline results are expected in the first half of 2023, and if positive, they would allow us to start pivotal studies in rrNHL and rrCLL shortly afterwards.

In a next step, our aim is to leverage CellPoint's platform with AboundBio's next-generation fully human multi-specific and multi-paratopic CAR-Ts that have the potential for deeper, more durable responses to treatment as well as retreatment of patients who relapsed following earlier CAR-T treatment. Our near-term goal is to bring three additional differentiated, next-generation CAR-T candidates in the clinic over the next three years.

[1] Chimeric antigen receptor T-cell
[2] Relapsed/Refractory NHL: non-Hodgkin Lymphoma, CLL: Chronic Lymphocytic Leukemia

In light of the ongoing scientific and strategic review and capital allocation prioritization, we decided to discontinue 4 early-stage programs: GLPG3121, a local release formulation JAK1/TYK2 inhibitor with potential in inflammatory diseases; GLPG0555, a JAK1 inhibitor evaluated in osteoarthritis; GLPG4586, a compound with undisclosed mode of action directed toward fibrosis; and GLPG4716, a chitinase inhibitor directed toward idiopathic pulmonary fibrosis. We continue to explore additional business development opportunities to further leverage our internal capabilities and renew our portfolio, and plan to provide a detailed update on our corporate strategy and portfolio later this year.

Portfolio



Our Jyseleca franchise is performing very well with robust sales momentum, supported by the regulatory approvals in ulcerative colitis (UC) in Great Britain and Japan earlier this year. Despite being the 4th JAK inhibitor to market, the adoption of Jyseleca is strong across Europe. As of 30 June 2022, Jyseleca is reimbursed in 15 countries for rheumatoid arthritis (RA) and 6 countries for UC, and we realized €35.4 million in net sales in the first half year of 2022.

We ended the first six months of the year with a strong balance sheet of €4.4 billion in cash and current financial investments, which provides us with the necessary means to execute for additional external innovation and accelerate our R&D pipeline. Following the acquisitions of CellPoint and AboundBio, we expect that second half operating expenses will increase by approximately €30 million. Therefore, we revised our cash burn[3] guidance of €450-€490 million for the full year 2022 to €480-€520 million. As a result of the strong Jyseleca performance, we increase our full-year net sales guidance from €65-€75 million to €75-€85 million.

[3] We refer to the **financial highlights** for an explanation and reconciliation of this alternative liquidity measure

Year-to-date operational review

Commercial & regulatory progress

- Strong adoption across Europe with reimbursement for RA in 15 countries and for UC in 6 countries
- Sobi, our distribution and commercialization partner in Eastern and Central Europe, Portugal, Greece, and the Baltic countries, launched Jyseleca in RA in the Czech Republic and Portugal, resulting in €2 million milestone payments to Galapagos in H1
- Filed a type II variation for label update for Jyseleca based on data from the MANTA and MANTA-RAy studies
- At the EULAR[4] 2022 European Congress of Rheumatology, Galapagos hosted several expert sessions and presented 11 abstracts, further establishing us as a key European player in RA
- Article 20 pharmacovigilance procedure ongoing by the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), investigating the safety data of all JAK inhibitors for the treatment of certain chronic inflammatory disorders

Pipeline update

- Decided to move forward with GLPG3667 (TYK2 inhibitor) in dermatomyositis with the aim to start a Phase 2 study before year-end
- Discontinued development of 4 early-stage programs as part of ongoing scientific and strategic exercise: GLPG3121, a local release formulation JAK1/TYK2 inhibitor with potential in inflammatory diseases; GLPG0555, a JAK1 inhibitor evaluated in osteoarthritis; GLPG4586, a compound with undisclosed mode of action directed toward fibrosis; and GLPG4716, a chitinase inhibitor directed toward idiopathic pulmonary fibrosis

Corporate update

- Entered the field of oncology through the combined acquisitions of CellPoint and AboundBio in all-cash transactions
- Received a transparency notification from FMR LLC in Q2 indicating that its shareholding in Galapagos increased and crossed the 5% threshold, to 5.04% of the current outstanding Galapagos shares
- Raised €3.6 million through the exercise of subscription rights
- Created new subscription right plans, offering all Galapagos employees the opportunity to participate
- All proposed resolutions regarding the extraordinary and annual shareholders' meetings were adopted by Galapagos' shareholders on 26 April 2022

[4] European Alliance of Associations for Rheumatology

H1 2022 financial result

- Jyseleca net sales amount to €35.4 million
- Collaboration revenues of €238.6 million
- R&D expenditures of €249.5 million
- S&M and G&A expenses amounting to €134.0 million
- Net loss of €32.3 million
- Operational cash burn of €217.1 million
- Cash position at end of June 2022 of €4,429.0 million

Outlook 2022

We anticipate a Committee for Medicinal Products for Human Use (CHMP) opinion on the type II variation for the Jyseleca label, based on the data from the MANTA and MANTA-RAy studies around year-end. We also expect reimbursement decisions in most key European markets in UC and anticipate that Sobi will further progress with reimbursement discussions in RA and UC in Eastern and Central Europe, Greece, and the Baltic countries. As part of the ongoing article 20 pharmacovigilance procedure on all JAK inhibitors approved in Europe, we expect a CHMP opinion by the end of the year, followed by an adoption by the European Commission shortly afterwards.

Patient enrolment in the Phase 1/2a trials in rrNHL and rrCLL is progressing well and we anticipate that additional clinical sites will be active by year-end. We are on track to report topline results of both trials in the first half of next year.

We plan to progress TYK2 inhibitor GLPG3667 into a Phase 2 program in dermatomyositis with first patients potentially recruited around year-end.

Following the acquisitions of CellPoint and AboundBio, we revised our cash burn guidance for full year 2022 from €450-€490 million to €480-€520 million. Additionally, we increased our anticipated net sales guidance for Jyseleca between €75 and €85 million.

We want to thank you for your continued support of our exciting journey to make a true impact on human lives through cutting-edge science and exceptional people. We strongly believe that we are taking the right steps in our transformation to accelerate value creation and look forward to presenting an in-depth update on our strategy later this year.

Respectfully,

Dr. Paul Stoffels[5]
CEO and chairman of the board of directors

Bart Filius
President, COO & CFO

[5] Acting via Stoffels IMC BV

Potential external impact

COVID-19

The start of 2022 was globally marked by steeply increasing infection rates mainly due to the spreading of the highly infectious Omicron-variant. At Galapagos, we hence maintained the strict measures put in place by local governments to help prevent the spread of the COVID-19 virus and protect the physical and mental health of our staff during the first months of the year. In most places, the situation improved significantly during the second quarter and the measures taken could gradually be loosened. We nevertheless keep on continuously monitoring COVID-19 infection rates at global and at local level, and have now systems in place to react quicky where needed to guarantee business continuity. We report the following impacts:

- *Staff*
  At Galapagos, we maintained the measures put in place by local governments to help prevent the spread of the COVID-19 virus and protect the physical and mental health of our staff. The majority of our research staff continued to work from the office/labs. For teleworkable functions we continued the implementation of our hybrid working model launched in 2021, in locations where the ongoing COVID-19 situation and corresponding local governmental measures permitted us to do so. For those employees coming to the office, we maintained stringent cleaning and sanitation protocols, and we strictly respected social distancing policies at all times in order to minimize risk of exposure. We further kept our global and site-specific business continuity plans up-to-date and continued to take appropriate recommended precautions.

  We learned during the pandemic that most of the international travel could be replaced by virtual meetings, resulting in improved cost efficiency, a better work-life balance, and a reduced carbon footprint. The impact of this new way-of-working has been retained and has become part of our corporate travel guidance. On the other hand, we noticed during the month of March 2022, when infection rates lowered significantly, an increasing appetite to start meeting in person again and to attend professional (international) events. For those who needed to attend or organize events, we did implement a global policy providing guidance on how to safely organize or attend any such professional events, both internally and externally.

- *Research portfolio*
  By prioritizing the most advanced projects very early on, and increasing the flexibility of our staff in the labs within projects, we maintained our research delivery timelines, kept the compound management facility running at all times, and continued our early drug research and the implementation of new modalities for target or drug discovery.

  The scorecard of the research department objectives shows a similar productivity compared to previous years, indicating that we were able to minimize the impact of the COVID-19 pandemic, at least in the short term.

- *Development portfolio*
  We have a business continuity plan for our clinical development programs. We closely monitor each program in the context of the current global and local situation of the COVID-19 pandemic and the associated specific regulatory, institutional, government guidance and policies related to COVID-19. Within the boundaries of these guidelines and policies, and in consultation with our CROs and clinical trial sites, we applied various measures to minimize the impact of the COVID-19 pandemic on our clinical development programs, with the primary aim to ensure the safety of our trial participants and to preserve the data integrity and scientific validity of the trials. These measures were implemented on a case-by-case basis, tailored to the specific study and country needs at any given time, with specific attention paid to vulnerable populations and the use of investigational medicines with immunosuppressive properties. The measures include, amongst others, increased, transparent communication to all stakeholders and the direct supply of investigational medicines to patients. For each clinical trial, we actively monitor and document the impact of COVID-19 to mitigate its effect on the study where necessary and to facilitate the interpretation and reporting of results.

- *Manufacturing and supply chain*
  To date, there has been no impact to the commercial supply of filgotinib as the result of the COVID-19 pandemic. All sites involved in the manufacturing of filgotinib are established sites that currently manufacture other marketed products and are in good standing with the FDA and are GMP certified. We became marketing authorization holder of filgotinib in the European Economic Area and Great Britain at the end of 2021, and are responsible for the manufacturing of filgotinib. The same manufacturing sites that supplied Gilead continue to supply filgotinib except for secondary packaging and labelling for which a new vendor has been selected.

- *Commercial organization*
  The form of outreach of our commercial teams to physicians and hospitals was impacted by the COVID-19 pandemic and consequent travel restrictions, and thus became partially virtual. The teams invested in digital channels as part of the overall commercial build strategy, and these channels are being utilized during our ongoing commercial launch. Thus far we note no material impact on the relative competitiveness of our commercial operations due to travel restrictions, nor have the effects of COVID-19 impacted our ability to engage in market access discussions. Nevertheless, healthcare systems are under pressure across Europe, increasing the volatility in reimbursement procedures and potentially reducing the number of new therapy options initiated by healthcare providers.

Conflict in Ukraine

The armed conflict between Russia and Ukraine could cause a material disruption in our operations. We currently have ongoing clinical studies for filgotinib with CROs located in Ukraine and Russia. If our CROs experience disruptions to their business due to the military conflict in Ukraine and the sanctions against Russia, it could result in delays in our clinical development activities, including delay of our clinical development plans and timelines, or could cause interruptions in operations of regulatory authorities. The impact on ongoing pivotal studies such as DIVERSITY 1 has remained limited. We continue to monitor the situation and are taking measures to mitigate the impact on our ability to conduct clinical development activities. Interruptions or delays in our and our CROs' ability to meet expected clinical development deadlines or to comply with contractual commitments with respect to the same, could lead to delays in our overall developmental and commercialization timelines, which would adversely impact our ability to conduct clinical development activities and complete them on a timely basis. Since 24 February 2022, we have extended the focus of the business continuity plan to closely monitor each program in context of the currently ongoing Ukraine-Russia conflict and the associated specific regulatory, institutional, and government guidance and policies.

Financial highlights

Consolidated key figures

(thousands of €, if not stated otherwise)	Second quarter of 2022	Second quarter of 2021	Six months ended 30 June 2022	Six months ended 30 June 2021	Year ended 31 December 2021
Income statement					
Product net sales	20,945	377	35,356	456	14,753
Collaboration revenues	116,665	139,395	238,601	253,207	470,093
Cost of sales	(2,633)	(93)	(5,545)	(131)	(1,629)
R&D expenditure	(149,597)	(138,866)	(249,518)	(268,826)	(491,707)
S&M, G&A expenses	(71,670)	(60,861)	(134,009)	(105,819)	(210,855)
Other operating income	9,957	13,298	17,637	23,564	53,749
Operating loss	(76,332)	(46,750)	(97,478)	(97,548)	(165,596)
Net financial results	58,115	(18,209)	67,676	19,916	42,598
Taxes	(811)	630	(2,536)	473	(2,423)
Net loss from continuing operations	(19,028)	(64,329)	(32,338)	(77,159)	(125,422)
Net profit from discontinued operations, net of tax	-	-	-	22,191	22,191
Net loss	(19,028)	(64,329)	(32,338)	(54,968)	(103,231)
Balance sheet					
Cash and cash equivalents	972,796	2,642,639	972,796	2,642,639	2,233,368
Current financial investments	3,456,184	2,363,969	3,456,184	2,363,969	2,469,809
R&D incentives receivables	155,771	142,745	155,771	142,745	144,013
Assets	5,040,085	5,430,617	5,040,085	5,430,617	5,193,160
Shareholders' equity	2,646,898	2,663,473	2,646,898	2,663,473	2,643,362
Deferred income	2,159,553	2,565,292	2,159,553	2,565,292	2,364,701
Other liabilities	233,634	201,852	233,634	201,852	185,097

(thousands of €, if not stated otherwise)	Second quarter of 2022	Second quarter of 2021	Six months ended 30 June 2022	Six months ended 30 June 2021	Year ended 31 December 2021
Cash flow					
Operational cash burn	(139,721)	(95,527)	(217,102)	(223,196)	(564,840)
Cash flow used in operating activities	(141,772)	(81,922)	(203,740)	(203,131)	(503,827)
Cash flow generated from/used in (-) investing activities	(147,604)	182,194	(1,081,057)	682,053	541,238
Cash flow used in financing activities	(337)	(1,952)	(361)	(1,474)	(3,876)
Increase/decrease (-) in cash and cash equivalents	(289,712)	98,319	(1,285,158)	477,448	33,535
Effect of currency exchange rate fluctuation on cash and cash equivalents	8,229	(9,629)	24,586	22,121	56,763
Cash and cash equivalents at the end of the period	972,796	2,642,639	972,796	2,642,639	2,233,368
Current financial investments at the end of the period	3,456,184	2,363,969	3,456,184	2,363,969	2,469,809
Total current financial investments and cash and cash equivalents at the end of the period	4,428,980	5,006,608	4,428,980	5,006,608	4,703,177
Financial ratios					
Number of shares issued at the end of the period	65,728,511	65,522,521	65,728,511	65,522,521	65,552,721
Basic and diluted loss per share (€)	(0.29)	(0.98)	(0.49)	(0.84)	(1.58)
Share price at the end of the period (in €)	53.04	58.48	53.04	58.48	49.22
Total group employees at the end of the period (number)	1,344	1,397	1,344	1,397	1,309

Employees per site as of 30 June 2022

(total: 1,344 employees)



H1 2022 financial results

We reported product net sales of Jyseleca in Europe for the first six months of 2022 amounting to €35.4 million (€0.5 million in the first half-year of 2021). Our counterparties for the sales of Jyseleca were mainly hospitals and wholesalers located in Belgium, the Netherlands, France, Italy, Spain, Germany, Great Britain, Ireland, Austria, Norway, Sweden and Finland.

Cost of sales related to Jyseleca net sales in the first six months of 2022 amounted to €5.5 million.

Collaboration revenues amounted to €238.6 million for the first six months of 2022, compared to €253.2 million for the first six months of 2021.

Revenues recognized related to the collaboration agreement with Gilead for the filgotinib development were €115.3 million in the first six months of 2022 compared to €136.1 million for the same period last year. This decrease was due to a lower increase in the percentage of completion, partly offset by a higher revenue recognition of milestone payments strongly influenced by the milestone achieved related to the regulatory approval in Japan for UC in the first half-year of 2022.

The revenue recognition related to the exclusive access rights for Gilead to our drug discovery platform amounted to €114.9 million for the first six months of 2022 (€115.7 million for the same period last year).

We have recognized royalty income from Gilead for Jyseleca for €6.3 million in the first six months of 2022 (compared to €1.4 million in the same period last year) of which €3.6 million royalties on milestone income for UC approval in Japan.

Additionally, we recorded milestones of €2.0 million triggered by the first sale of Jyseleca in Czech Republic and Portugal by our distribution and commercialization partner Sobi, in the first half-year of 2022.

Our deferred income balance on 30 June 2022 includes €1.6 billion allocated to our drug discovery platform that is recognized linearly over the remaining period of our 10 year collaboration, and €0.5 billion allocated to filgotinib development that is recognized over time until the end of the development period.

Our R&D expenditure in the first six months of 2022 amounted to €249.5 million, compared to €268.8 million for the first six months of 2021. This decrease was primarily explained by a decrease in subcontracting costs from €139.2 million in the first half-year of 2021 to €104.1 million in the first half-year of 2022, primarily due to the winding down of the ziritaxestat (IPF) program and reduced spend on our Toledo (SIKi) and TYK2 programs. This was partly offset by cost increases for our filgotinib program, on a six month basis compared to the same period in 2021. Personnel costs decreased from €94.2 million in the first half of 2021 to €86.0 million for the same period this year mainly due to a lower number of FTEs as well as lower costs for our subscription right plans. Depreciation and impairment amounted to €32.6 million for the first six months of 2022 (€8.1 million for the same period last year). This increase was primarily due to an impairment of €26.7 million of previously capitalized upfront fees related to our collaboration with Molecure on the dual chitinase inhibitor OATD-01 (GLPG4716). As part of an ongoing strategic exercise to renew and accelerate our portfolio, we decided to return all rights to OATD-01 to Molecure.

Our S&M expenses were €71.0 million in the first six months of 2022, compared to €29.0 million in the first six months of 2021. This increase was primarily due to the termination of our 50/50 filgotinib co-commercialization cost sharing agreement with Gilead. The cost increase was also explained by an increase in personnel costs (€35.7 million for the first six months of 2022 compared to €26.9 million for the same period last year) explained by an increase in the commercial work force from 215 average FTEs in the first half-year of 2021 to 305 average FTEs in the first half-year of 2022 driven by the commercial launch of filgotinib in Europe.

Our G&A expenses were €63.0 million in the first six months of 2022, compared to €76.9 million in the first six months of 2021. The cost decrease was primarily due to the exceptional impairment of €9.3 million on other tangible assets recorded in the first six months of 2021 following our decision to reassess the construction project of our new future headquarter location in Mechelen (Belgium). Personnel costs (€35.6 million for the first six months of 2022 compared to €37.6 million for the same period last year) decreased primarily explained by a lower number of FTEs.

Other operating income (€17.6 million for the first six months of 2022, compared to €23.6 million for the first six months of 2021) decreased by €5.9 million, mainly driven by lower grant and R&D incentive income.

We reported an operating loss amounting to €97.5 million for the first six months of 2022, compared to an operating loss of €97.6 million for the same period last year.

Net financial income in the first six months of 2022 amounted to €67.7 million (as compared to net financial income of €19.9 million in the same period last year). Net financial income in the first six months of 2022 was primarily attributable to €57.4 million of unrealized currency exchange gain on our cash and cash equivalents and current financial investments at amortized cost in U.S. dollar (as compared to €33.4 million currency exchange gain on cash and cash equivalents and current financial investments in the first six months of 2021) and €11.8 million positive changes in (fair) value of current financial investments (€5.8 million negative changes in the same period last year). The other financial expenses also contained the effect of discounting our long term deferred income of €3.8 million (€4.8 million in the same period last year). The fair value loss of financial assets held at fair value through profit or loss amounted to nil in the first six months in 2022 (as compared to €2.9 million in the same period last year).

We realized a net loss from continuing operations of €32.3 million for the first six months of 2022, compared to a net loss of €77.2 million for the first six months of 2021.

The net profit from discontinued operations for the first six months of 2021 consisted of the gain on the sale of Fidelta, our fee-for-services business, for €22.2 million.

We reported a group net loss for the first six months of 2022 of €32.3 million, compared to a net loss of €55.0 million for the same period last year.

Cash, cash equivalents and current financial investments

Cash and cash equivalents and current financial investments totaled €4,429.0 million on 30 June 2022 (€4,703.2 million on 31 December 2021).

A net decrease of €274.2 million in cash and cash equivalents and current financial investments was recorded during the first six months of 2022, compared to a net decrease of €162.7 million during the first six months of 2021. This net decrease was composed of (i) €217.1 million of operational cash burn, (ii) offset by €3.6 million of cash proceeds from capital and share premium increases from exercise of subscription rights in the first six months of 2022, (iii) €11.8 million of positive changes in (fair) value of current financial investments and €60.4 million of mainly positive exchange rate differences, and (iv) €132.9 million cash out from the acquisitions of CellPoint and AboundBio, net of cash acquired.

The operational cash burn (or operational cash flow if this liquidity measure is positive) is a financial measure that is not calculated in accordance with IFRS. Operational cash burn/cash flow is defined as the increase or decrease in our cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus:

i. the net proceeds, if any, from share capital and share premium increases included in the net cash flows generated from/used in (–) financing activities

ii. the net proceeds or cash used, if any, in acquisitions or disposals of businesses; the movement in restricted cash and movement in current financial investments, if any, the loans and advances given to third parties, if any, included in the net cash flows generated from/used in (–) investing activities

iii. the cash used for other liabilities related to the acquisition of businesses, if any, included in the net cash flows generated from/used in (-) operating activities.

This alternative liquidity measure is in our view an important metric for a biotech company in the development stage.

The following table provides a reconciliation of the operational cash burn:

	Six months ended 30 June	
(thousands of €)	**2022**	2021
Increase/decrease (-) in cash and cash equivalents (excluding effect of exchange differences)	(1,285,158)	477,448
Less:		
Net proceeds from capital and share premium increases	(3,619)	(2,583)
Net purchase/sale (-) of current financial investments	938,732	(669,365)
Cash out from acquisition of subsidiaries, net of cash acquired	115,178	-
Cash advances and loans to third parties	10,000	-
Cash used for other liabilities related to the acquisition of subsidiaries	7,765	-
Cash in from disposals of subsidiaries, net of cash disposed of	-	(28,696)
Total operational cash burn	**(217,102)**	**(223,196)**

Risk factors

We refer to the **description of risk factors in our 2021 annual report**, pp. 57-69, as supplemented by the description of risk factors in our annual report on Form 20-F filed with the U.S. Securities and Exchange Commission, pp. 6-50. In summary of the foregoing, the principal risks and uncertainties faced by us relate to and include, but are not limited to: commercialization, product development and regulatory approval; our financial position and need for additional capital; our reliance on third parties; our competitive position; our intellectual property; our organization, structure and operation (including the emergence of pandemics such as COVID-19); and market risks relating to our shares and ADSs.

We also refer to the **description of the group's financial risk management given in the 2021 annual report**, pp. 250-254, which remains valid and unaltered.

The Galapagos share

Performance of the Galapagos share on Euronext and Nasdaq

Related party transactions

We refer to the statements included under the heading Related party transactions in the "**Notes to the unaudited condensed consolidated interim financial statements for the first six months of 2022**" part of this report.

Disclaimer and other information

Galapagos NV is a limited liability company organized under the laws of Belgium, having its registered office at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium. Throughout this report, the term "Galapagos NV" refers solely to the non-consolidated Belgian company and references to "we," "our," "the group" or "Galapagos" include Galapagos NV together with its subsidiaries.

With the exception of filgotinib's approval as Jyseleca® for the treatment of rheumatoid arthritis and ulcerative colitis by the European Commission, Great Britain's Medicines and Healthcare products Regulatory Agency and Japanese Ministry of Health, Labour and Welfare, our drug candidates mentioned in this report are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority.

This report is published in Dutch and in English. In case of inconsistency between the Dutch and the English version, the Dutch version shall prevail. Galapagos is responsible for the translation and conformity between the Dutch and English version.

This report is available free of charge and upon request addressed to:

Galapagos NV
Investor Relations
Generaal De Wittelaan L11 A3
2800 Mechelen, Belgium
Tel: +32 15 34 29 00
Email: ir@glpg.com

A digital version of this report is available on our website, www.glpg.com.

We will use reasonable efforts to ensure the accuracy of the digital version, but we do not assume responsibility if inaccuracies or inconsistencies with the printed document arise as a result of any electronic transmission. Therefore, we consider only the printed version of this report to be legally valid. Other information on our website or on other websites does not form a part of this report.

Listings

Euronext Amsterdam and Brussels: GLPG
Nasdaq: GLPG

Forward-looking statements

This report contains forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "believe," "anticipate," "expect," "intend," "plan," "seek," "estimate," "may," "will," "could," "would," "potential," "forward," "goal," "next," "stand to," "continue," "should," "encouraging," "aim," "explore," "further" as well as similar expressions. Forward-looking statements contained in this report include, but are not limited to, statements made in the **"Letter to our shareholders"** section of this report, the information provided in the section captioned "Outlook 2022", the guidance from management regarding the expected operational use of cash during financial year 2022, statements regarding our strategic and capital allocation priorities, statements regarding the acquisitions of CellPoint and AboundBio, including statements regarding anticipated benefits of the acquisitions and the integration of CellPoint and AboundBio into our portfolio and strategic plans, statements regarding our regulatory and R&D outlook, statements regarding expected financial results, statements regarding the amount and timing of potential future milestones, opt-in and/or royalty payments, our R&D strategy, including progress on our fibrosis portfolio and our SIK platform, and potential changes in such strategy, statements regarding our pipeline and complementary technology platforms driving future growth, statements regarding the strategic re-evaluation, statements regarding our expectations on commercial sales of filgotinib, statements regarding the global R&D collaboration with Gilead and the amendment of our arrangement with Gilead for the commercialization and development of filgotinib, statements regarding the expected timing, design and readouts of ongoing and planned clinical trials (or the discontinuation thereof) (i) with filgotinib in RA, UC and Crohn's disease, (ii) with GLPG0555 in osteoarthritis, (iii) with GLPG3121 in IBD, (iv) with GLPG3667 in psoriasis and dermatomyositis, (v) with GLPG4399 in inflammation, (vi) with compounds from our SIKi portfolio, (vii) with GLPG4716 in IPF, (viii) with GLPG4586 and GLPG4605 in fibrosis, (ix) with GLPG2737 in ADPKD, (x) with CD19 CAR-T in 2 Phase 1/2a studies in rrNHL and rrCLL, and (xi) with the next-generation CAR-Ts and bispecific antibodies, including recruitment for trials and topline results for trials and studies in CAR-T, statements related to the EMA's safety review of JAK inhibitors used to treat certain inflammatory disorders, including filgotinib, initiated at the request of the European Commission (EC) under article 20 of Regulation (EC) No 726/2004, statements relating to interactions with regulatory authorities, the timing or likelihood of additional regulatory authorities' approval of marketing authorization for filgotinib for RA, UC or any other indication for filgotinib in Europe, Great Britain, Japan, and the U.S., such additional regulatory authorities requiring additional studies, the timing or likelihood of pricing and reimbursement interactions for filgotinib, statements relating to the build-up of our commercial organization, commercial sales for filgotinib and rollout in Europe, statements regarding the effect of the conflict between Russia and Ukraine on our operations and ongoing studies (including the impact on our DIVERSITY 1 study), statements regarding the expected impact of COVID-19, and statements regarding our strategy, business plans and focus. We caution the reader that forward-looking statements are based on our management's current expectations and beliefs, and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause our actual results, financial condition and liquidity, performance or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Such risks include, but are not limited to, the risk that our beliefs, assumptions and expectations regarding our 2022 revenues and financial results or our 2022 operating expenses may be incorrect (including because one

or more of our assumptions underlying our revenue or expense expectations may not be realized), the inherent risks and uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including, but not limited to, the risk that data from our ongoing and planned clinical research programs in RA, rrNHL, rrCLL, Crohn's disease, UC, IPF, osteoarthritis, other inflammatory indications and kidney disease or any other indication or disease, may not support registration or further development of our product candidates due to safety, or efficacy concerns, or other reasons), risks related to the acquisitions of CellPoint and AboundBio, including the risk that we may not achieve the anticipated benefits of the acquisitions of CellPoint and AboundBio, the inherent risks and uncertainties associated with target discovery and validation and drug discovery and development activities, risks related to our reliance on collaborations with third parties (including our collaboration partner Gilead), risks related to the implementation of the transition of the European commercialization responsibility of filgotinib from Gilead to us, the risk that the transition will not be completed on the currently contemplated timeline or at all, including the transition of the supply chain, and the risk that the transition will not have the currently expected results for our business and results of operations, the risk that estimates regarding our filgotinib development program and the commercial potential of our product candidates and our expectations regarding the costs and revenues associated with the transfer of European commercialization rights to filgotinib may be incorrect, the risk that we will not be able to continue to execute on our currently contemplated business plan and/or will revise our business plan, including the risk that our plans with respect to CAR-T may not be achieved on the currently anticipated timeline or at all, the risk that our projections and expectations regarding the commercial potential of our product candidates or expectations regarding the costs and revenues associated with the commercialization rights may be inaccurate, the risk that we will be unable to successfully achieve the anticipated benefits from our leadership transition plan, the risk that we will encounter challenges retaining or attracting talent, risks related to disruption in our operations due to the conflict between Russia and Ukraine, the risks related to continued regulatory review of filgotinib following approval by relevant regulatory authorities and the EMA's safety review of JAK inhibitors used to treat certain inflammatory disorders, including the risk that the EMA and/or other regulatory authorities determine that additional non-clinical or clinical studies are required with respect to filgotinib, the risk that the EMA may require that the market authorization for filgotinib in the EU be amended, the risk that the EMA may impose JAK class-based warnings, the risk that the EMA's safety review may negatively impact acceptance of filgotinib by patients, the medical community and healthcare payors and the risks and uncertainties related to the impact of the COVID-19 pandemic. A further list and description of these risks, uncertainties and other risks can be found in our filings and reports with the Securities and Exchange Commission (SEC), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. We also refer to the "**Risk Factors**" section of this report. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this document. We expressly disclaim any obligation to update any such forward-looking statements in this document to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

Financial statements

Unaudited condensed consolidated interim financial statements for the first half-year of 2022

Foundation & Future

Unaudited condensed consolidated interim financial statements for the first six months of 2022

Consolidated statements of income and comprehensive income/loss (-)

(unaudited)

Consolidated income statement

	Second quarter of		Six months ended 30 June	
(thousands of €, except per share data)	**2022**	2021	**2022**	2021
Product net sales	20,945	377	35,356	456
Collaboration revenues	116,665	139,395	238,601	253,207
Total net revenues	**137,610**	139,772	**273,957**	**253,664**
Cost of sales	(2,633)	(93)	(5,545)	(131)
Research and development expenditure	(149,597)	(138,866)	(249,518)	(268,826)
Sales and marketing expenses	(42,024)	(14,425)	(71,008)	(28,961)
General and administrative expenses	(29,646)	(46,436)	(63,001)	(76,858)
Other operating income	9,957	13,298	17,637	23,564
Operating loss	**(76,332)**	(46,750)	**(97,478)**	(97,548)
Fair value adjustments and net currency exchange differences	58,858	(13,500)	71,929	27,695
Other financial income	3,320	730	4,015	1,568
Other financial expenses	(4,062)	(5,439)	(8,268)	(9,347)
Loss before tax	**(18,217)**	(64,959)	**(29,802)**	(77,632)
Income taxes	(811)	630	(2,536)	473
Net loss from continuing operations	**(19,028)**	(64,329)	**(32,338)**	(77,159)

	Second quarter of		Six months ended 30 June	
(thousands of €, except per share data)	2022	2021	2022	2021
Net profit from discontinued operations, net of tax	-	-	-	22,191
Net loss	(19,028)	(64,329)	(32,338)	(54,968)
Net loss attributable to:				
Owners of the parent	(19,028)	(64,329)	(32,338)	(54,968)
Basic and diluted loss per share	(0.29)	(0.98)	(0.49)	(0.84)
Basic and diluted loss per share from continuing operations	(0.29)	(0.98)	(0.49)	(1.18)

The accompanying notes form an integral part of these condensed consolidated financial statements.

Consolidated statement of comprehensive income/loss (-)

	Second quarter of		Six months ended 30 June	
(thousands of €)	2022	2021	2022	2021
Net loss	**(19,028)**	(64,329)	**(32,338)**	(54,968)
Items that may be reclassified subsequently to profit or loss:				
Translation differences, arisen from translating foreign activities	112	(95)	93	203
Realization of translation differences upon sale of foreign operations	-	-	-	731
Other comprehensive income/loss (-), net of income tax	**112**	(95)	**93**	934
Total comprehensive loss attributable to:				
Owners of the parent	(18,916)	(64,424)	(32,245)	(54,034)
Total comprehensive loss attributable to owners of the parent arises from:				
Continuing operations	(18,916)	(64,424)	(32,245)	(76,956)
Discontinued operations	-	-	-	22,922
Total comprehensive loss	**(18,916)**	**(64,424)**	**(32,245)**	**(54,034)**

The accompanying notes form an integral part of these condensed consolidated financial statements.

Consolidated statements of financial position

(unaudited)

(thousands of €)	30 June 2022	31 December 2021
Assets		
Goodwill	174,288	-
Intangible assets other than goodwill	32,346	60,103
Property, plant and equipment	148,866	137,512
Deferred tax assets	4,060	4,032
Non-current R&D incentives receivables	138,945	127,186
Other non-current assets	8,390	2,473
Non-current assets	**506,893**	**331,306**
Inventories	27,008	20,569
Trade and other receivables	47,231	111,337
Current R&D incentives receivables	16,826	16,827
Current financial investments	3,456,184	2,469,809
Cash and cash equivalents	972,796	2,233,368
Other current assets	13,147	9,945
Current assets	**4,533,192**	**4,861,854**
Total assets	**5,040,085**	**5,193,160**

(thousands of €)	30 June 2022	31 December 2021
Equity and liabilities		
Share capital	293,026	292,075
Share premium account	2,733,059	2,730,391
Other reserves	(10,493)	(10,177)
Translation differences	(1,313)	(1,722)
Accumulated losses	(367,381)	(367,205)
Total equity	**2,646,898**	**2,643,362**
Retirement benefit liabilities	12,162	11,699
Non-current lease liabilities	16,875	19,655
Other non-current liabilities	35,948	7,135
Non-current deferred income	1,777,477	1,944,836
Non-current liabilities	**1,842,462**	**1,983,325**
Current lease liabilities	7,179	7,204
Trade and other liabilities	160,746	137,622
Current tax payable	723	1,782
Current deferred income	382,076	419,866
Current liabilities	**550,725**	**566,474**
Total liabilities	**2,393,187**	**2,549,798**
Total equity and liabilities	**5,040,085**	**5,193,160**

The accompanying notes form an integral part of these condensed consolidated financial statements.

Consolidated cash flow statements

(unaudited)

	Six months ended 30 June	
(thousands of €)	2022	2021
Net loss of the period	**(32,338)**	**(54,968)**
Adjustment for non-cash transactions	6,567	50,310
Adjustment for items to disclose separately under operating cash flow	3,529	2,518
Adjustment for items to disclose under investing and financing cash flows	(416)	(28,843)
Change in working capital other than deferred income	46,034	81,359
Cash used for other liabilities related to the acquisition of subsidiaries	(7,765)	-
Decrease in deferred income	(209,428)	(248,610)
Cash used in operations	**(193,818)**	**(198,234)**
Interest paid	(7,417)	(5,862)
Interest received	757	1,237
Corporate taxes paid	(3,262)	(272)
Net cash flows used in operating activities	**(203,740)**	**(203,131)**

	Six months ended 30 June	
(thousands of €)	**2022**	**2021**
Purchase of property, plant and equipment	(15,574)	(19,414)
Purchase of and expenditure in intangible fixed assets	(1,783)	(647)
Purchase of current financial investments	(1,842,495)	(703,841)
Interest received related to current financial investments	210	8
Sale of current financial investments	903,763	1,373,206
Cash in from disposals of subsidiaries, net of cash disposed of	-	28,696
Cash out from acquisition of subsidiaries, net of cash acquired	(115,178)	-
Cash advances and loans to third parties	(10,000)	-
Proceeds from sale of financial assets held at fair value through profit or loss	-	4,045
Net cash flows generated from/used in (-) investing activities	**(1,081,057)**	**682,053**
Payment of lease liabilities	(3,980)	(4,057)
Proceeds from capital and share premium increases from exercise of subscription rights	3,619	2,583
Net cash flows used in financing activities	**(361)**	**(1,474)**
Increase/decrease (-) in cash and cash equivalents	**(1,285,158)**	**477,448**
Cash and cash equivalents at beginning of year	**2,233,368**	**2,143,071**
Increase/decrease (-) in cash and cash equivalents	(1,285,158)	477,448
Effect of exchange rate differences on cash and cash equivalents	24,586	22,121
Cash and cash equivalents at end of the period	**972,796**	**2,642,639**

The accompanying notes form an integral part of these condensed consolidated financial statements.

	30 June	
(thousands of €)	2022	2021
Current financial investments	3,456,184	2,363,969
Cash and cash equivalents	972,796	2,642,639
Current financial investments and cash and cash equivalents	**4,428,980**	**5,006,608**

The accompanying notes form an integral part of these condensed consolidated financial statements.

Consolidated statements of changes in equity

(unaudited)

(thousands of €)	Share capital	Share premium account	Translation differences	Other reserves	Accumul. losses	Total
On 1 January 2021	291,312	2,727,840	(3,189)	(10,907)	(334,701)	**2,670,355**
Net loss					(54,968)	**(54,968)**
Other comprehensive income			795	139		934
Total comprehensive income/loss (-)			**795**	**139**	(54,968)	**(54,034)**
Share-based compensation					44,568	44,568
Exercise of subscription rights	599	1,984				2,583
On 30 June 2021	291,912	2,729,824	(2,394)	(10,768)	(345,101)	**2,663,473**
On 1 January 2022	292,075	2,730,391	(1,722)	(10,177)	(367,205)	**2,643,362**
Net loss					(32,338)	**(32,338)**
Other comprehensive income/loss (-)			409	(316)		93
Total comprehensive income/loss (-)			**409**	**(316)**	(32,338)	**(32,245)**
Share-based compensation					32,163	32,163
Exercise of subscription rights	951	2,668				3,619
On 30 June 2022	293,026	2,733,059	(1,313)	(10,493)	(367,381)	**2,646,898**

The accompanying notes form an integral part of these condensed consolidated financial statements.

Notes to the unaudited condensed consolidated interim financial statements for the first six months of 2022

Basis of preparation

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 'Interim Financial Reporting' as adopted by the European Union and as issued by the IASB. The condensed consolidated interim financial statements do not contain all information required for an annual report and should therefore be read in conjunction with our Annual Report 2021.

Impact of COVID-19 on the financial statements

To date, we have experienced limited impact on our financial performance, financial position, cash flows and significant judgements and estimates, although we continue to face additional risks and challenges associated with the impact of the outbreak.

Significant accounting policies

There were no significant changes in accounting policies applied by us in these condensed consolidated interim financial statements compared to those used in the most recent annual consolidated financial statements of 31 December 2021.

New standards and interpretations applicable for the annual period beginning on 1 January 2022 did not have any material impact on our condensed consolidated interim financial statements.

We have not early adopted any other standard, interpretation, or amendment that has been issued but is not yet effective.

New accounting policies as a result of recent transactions

Business combinations

Business combinations are accounted for using the acquisition method. In the statement of financial position, the acquiree's identifiable assets, liabilities and contingent liabilities are initially recognized at their fair value at the acquisition date. The results of acquired operations are included in our consolidated income statement from the date on which control is obtained. Any contingent consideration to be transferred by us will be recognized at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration, which is deemed to be an asset or liability, will be recognized in profit or loss. The excess of the fair value of the total purchase consideration transferred over the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The valuations in support of fair value determinations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred.

Key sources of estimation uncertainty

Acquisition of CellPoint

We determine and allocate the purchase price relating to the acquisition of CellPoint to the assets acquired and liabilities assumed as of the acquisition date, being 21 June 2022. The purchase price determination process requires us to use significant estimates and assumptions that determine the present fair value of the contingent consideration included in the transaction. These estimates depend on development, regulatory and sales-based milestones that are adjusted by our best estimate of their probability of success and discounted. We also anticipate to use significant estimates and assumptions in the finalization of the purchase price accounting process.

Details of the unaudited condensed consolidated interim results

Product net sales

We reported net sales of Jyseleca for the first six months of 2022 amounting to €35.4 million (€0.5 million in the first six months of 2021).

Related costs of sales in the first half-year of 2022 amounted to €5.5 million.

Collaboration revenues

The following table summarizes our collaboration revenues for the six months ended 30 June 2022 and 2021:

			Second quarter of		Six months ended 30 June	
(thousands of €)	Over time	Point in time	2022	2021	2022	2021
Recognition of non-refundable upfront payments and license fees			**105,384**	**127,215**	**204,301**	**232,441**
Gilead collaboration agreement for filgotinib	✓		47,784	69,339	89,385	116,744
Gilead collaboration agreement for drug discovery platform	✓		57,601	57,876	114,916	115,697
Milestone payments			**9,564**	**11,504**	**27,938**	**19,369**
Gilead collaboration agreement for filgotinib	✓		8,564	11,504	25,938	19,369
Sobi distribution agreement for Jyseleca		✓	1,000	-	2,000	-
Royalties			**1,716**	**676**	**6,361**	**1,397**
Gilead royalties on Jyseleca		✓	1,716	672	6,317	1,350
Other royalties		✓	-	4	44	47
Total collaboration revenues			**116,665**	**139,395**	**238,601**	**253,207**

The rollforward of the outstanding balance of the current and non-current deferred income between 1 January 2022 and 30 June 2022 can be summarized as follows:

(thousands of €)	Total	Gilead collaboration agreement for filgotinib	Gilead collaboration agreement for drug discovery platform [1]	Other deferred income
On 1 January 2022	**2,364,701**	**604,875**	**1,759,828**	**-**
Milestones achieved	18,238	18,238		
Significant financing component [2]	3,799	3,799		
Revenue recognition of upfront	(204,301)	(89,385)	(114,916)	
Revenue recognition of milestones	(25,938)	(25,938)		
Other movements	3,053			3,053
On 30 June 2022	**2,159,553**	**511,588**	**1,644,912**	**3,053**

[1] The upfront received and the outstanding balance at 1 January 2022 and at 30 June 2022 comprise the issuance liabilities for the warrants and the upfront payment allocated to the drug discovery platform.
[2] With regard to the additional consideration received for the extended cost sharing for filgotinib, we assume the existence of a significant financing component reflecting the time value of money on the estimated recognition period.

Operating costs and other operating income

Operating costs

Research and development expenditure

The following table summarizes our research and development expenditure for the six months ended 30 June 2022 and 2021:

	Second quarter of		Six months ended 30 June	
(thousands of €)	2022	2021	2022	2021
Personnel costs	(45,752)	(53,772)	(85,957)	(94,154)
Subcontracting	(62,332)	(66,213)	(104,060)	(139,193)
Disposables and lab fees and premises costs	(5,103)	(6,370)	(10,310)	(12,287)
Depreciation and impairment	(29,169)	(4,816)	(32,555)	(8,099)
Professional fees	(2,994)	(3,828)	(7,402)	(7,041)
Other operating expenses	(4,249)	(3,867)	(9,234)	(8,052)
Total research and development expenditure	**(149,597)**	**(138,866)**	**(249,518)**	**(268,826)**

The increase in depreciation and impairment for the first six months of 2022 is primarily due to an impairment of €26.7 million of previously capitalized upfront fees related to our collaboration with Molecure on the dual chitinase inhibitor OATD-01.

The table below summarizes our R&D expenditure for the six months ended 30 June 2022 and 2021, broken down by program.

	Second quarter of		Six months ended 30 June	
(thousands of €)	2022	2021	2022	2021
Filgotinib program	(71,280)	(50,908)	(116,147)	(87,840)
Toledo program	(12,744)	(24,412)	(26,098)	(52,235)
TYK2 program on GLPG3667	(5,611)	(7,984)	(9,078)	(13,974)
Ziritaxestat program	(106)	(8,905)	(638)	(19,418)
Other programs	(59,856)	(46,657)	(97,557)	(95,359)
Total research and development expenditure	**(149,597)**	**(138,866)**	**(249,518)**	**(268,826)**

Sales and marketing expenses

The following table summarizes our sales and marketing expenses for the six months ended 30 June 2022 and 2021:

	Second quarter of		Six months ended 30 June	
(thousands of €)	2022	2021	2022	2021
Personnel costs	(19,690)	(16,569)	(35,723)	(26,871)
Depreciation	(907)	(117)	(1,122)	(168)
External outsourcing costs	(15,293)	(14,844)	(25,671)	(24,959)
Sales and marketing expenses recharged to Gilead	-	18,885	31	25,527
Professional fees	(1,165)	(162)	(1,534)	(180)
Other operating expenses	(4,970)	(1,618)	(6,989)	(2,310)
Total sales and marketing expenses	**(42,024)**	**(14,425)**	**(71,008)**	**(28,961)**

The termination of our 50/50 filgotinib co-commercialization cost sharing agreement with Gilead explains a significant part of the increase in sales & marketing expenses.

General and administrative expenses

The following table summarizes our general and administrative expenses for the six months ended 30 June 2022 and 2021:

	Second quarter of		Six months ended 30 June	
(thousands of €)	2022	2021	2022	2021
Personnel costs	(15,211)	(21,361)	(35,629)	(37,568)
Depreciation and impairment	(2,383)	(11,060)	(4,297)	(12,730)
Legal and professional fees	(6,309)	(7,610)	(10,817)	(13,469)
Other operating expenses	(5,744)	(6,406)	(12,259)	(13,092)
Total general and administrative expenses	**(29,646)**	**(46,436)**	**(63,001)**	**(76,858)**

Other operating income

The following table summarizes our other operating income for the six months ended 30 June 2022 and 2021:

	Second quarter of		Six months ended 30 June	
(thousands of €)	**2022**	**2021**	**2022**	**2021**
Grant income	572	2,515	1,009	3,787
R&D incentives	8,818	10,656	15,903	19,502
Other	567	128	725	276
Total other operating income	**9,957**	**13,298**	**17,637**	**23,564**

Financial income/expenses

The following table summarizes our financial income/expenses (-) for the six months ended 30 June 2022 and 2021:

	Second quarter of		Six months ended 30 June	
(thousands of €)	2022	2021	2022	2021
Fair value adjustments and net currency exchange differences				
Net currency exchange gain/loss (-)	46,718	(12,096)	60,168	33,613
Fair value re-measurement of warrants	136	858	(49)	2,828
Fair value loss on financial assets held at fair value through profit or loss	-	-	-	(2,913)
Fair value gain/loss (-) on current financial investments	12,004	(2,262)	11,810	(5,833)
Total fair value adjustments and net currency exchange differences	**58,858**	**(13,500)**	**71,929**	**27,695**
Other financial income:				
Interest income	2,956	696	3,618	1,442
Effect of discounting long term R&D incentives receivables	23	23	46	46
Other finance income	341	11	351	80
Total other financial income	**3,320**	**730**	**4,015**	**1,568**
Other financial expenses:				
Interest expenses	(2,142)	(3,050)	(4,206)	(4,425)
Effect of discounting long term deferred income	(1,860)	(2,323)	(3,799)	(4,770)
Other finance charges	(60)	(66)	(264)	(152)
Total other financial expenses	**(4,062)**	**(5,439)**	**(8,268)**	**(9,347)**
Total net financial result	**58,115**	**(18,209)**	**67,676**	**19,916**

Cash position

Cash and cash equivalents and current financial investments totaled €4,429.0 million on 30 June 2022 (€4,703.2 million on 31 December 2021).

Cash and cash equivalents and current financial investments comprised cash at banks, term deposits, treasury bills and money market funds. Our cash management strategy monitors and optimizes our liquidity position. Our cash management strategy allows short-term deposits with an original maturity exceeding three months while monitoring all liquidity aspects.

Cash and cash equivalents comprised €487.8 million of term deposits which all had an original maturity longer than three months. All cash and cash equivalents are available upon maximum three months notice period and without significant penalty. Cash at banks were mainly composed of notice accounts and current accounts. Our credit risk is mitigated by selecting a panel of highly rated financial institutions for our deposits.

Current financial investments comprised €1,332.9 million of term deposits which all had an original maturity longer than three months and which are not available on demand within three months. Our current financial investments also comprised money market funds and treasury bills. Our portfolio of treasury bills contains only AAA rated paper, issued by Germany. Our money market funds portfolio consists of AAA short-term money market funds with a diversified and highly rated underlying portfolio managed by established fund management companies with a proven track record.

	30 June	31 December
(thousands of €)	2022	2021
Money market funds	1,295,726	1,317,460
Treasury bills	827,574	877,349
Term deposits	1,332,884	275,000
Total current financial investments	**3,456,184**	**2,469,809**
Cash at banks	485,031	1,225,860
Term deposits	487,765	1,007,508
Total cash and cash equivalents	**972,796**	**2,233,368**
Total current financial investments and cash and cash equivalents	**4,428,980**	**4,703,177**

On 30 June 2022, our cash and cash equivalents and current financial investments included $953.8 million held in U.S. dollars ($942.5 million on 31 December 2021) which could generate foreign exchange gains or losses in our financial results in accordance with the fluctuation of the EUR/U.S. dollar exchange rate as our functional currency is EUR. The foreign exchange loss (–)/gain in case of a 10% change in the EUR/U.S. dollar exchange rate amounts to €91.8 million.

Capital increase

On 30 June 2022, Galapagos NV's share capital was represented by 65,728,511 shares. All shares were issued, fully paid up and of the same class. The below table summarizes our capital increases for the period ended 30 June 2022.

(thousands of €, except share data)	Number of shares	Share capital	Share premium	Share capital and share premium	Average exercise price subscription rights (in €/ subscription right)	Closing share price on date of capital increase (in €/ share)
On 1 January 2022	65,552,721	292,075	2,730,391	3,022,467		
18 March 2022: exercise of subscription rights	95,500	517	1,643	2,160	22.61	57.38
20 June 2022: exercise of subscription rights	80,290	434	1,025	1,460	18.18	53.52
On 30 June 2022	65,728,511	293,026	2,733,059	3,026,086		

Note to the cash flow statement

	Six months ended 30 June	
(thousands of €)	2022	2021
Adjustment for non-cash transactions		
Depreciation and impairment	37,974	20,996
Share-based compensation expenses	32,163	44,568
Increase in retirement benefit obligations and provisions	270	190
Unrealized exchange gains and non-cash other financial result	(59,627)	(26,537)
Discounting effect of deferred income	3,799	4,770
Fair value re-measurement of warrants	49	(2,828)
Net change in (fair) value of current financial investments	(11,810)	5,833
Fair value adjustment financial assets held at fair value through profit or loss	-	2,913
Other non-cash expenses	3,750	405
Total adjustment for non-cash transactions	**6,567**	**50,310**
Adjustment for items to disclose separately under operating cash flow		
Interest expense	4,206	4,425
Interest income	(3,214)	(1,434)
Tax expense	2,536	(473)
Total adjustment for items to disclose separately under operating cash flow	**3,529**	**2,518**
Adjustment for items to disclose under investing and financing cash flows		
Gain on sale of subsidiaries	-	(22,191)
Gain (-)/loss on sale of fixed assets	(11)	1
Realized exchange gain on sale of current financial investments	-	(6,645)
Interest income on current financial assets	(405)	(8)
Total adjustment for items to disclose separately under investing and financing cash flow	**(416)**	**(28,843)**

(thousands of €)	Six months ended 30 June 2022	2021
Change in working capital other than deferred income		
Increase in inventories	(10,195)	(1,419)
Decrease in receivables	53,204	107,041
Increase/decrease (-) in liabilities	3,025	(24,263)
Total change in working capital other than deferred income	**46,034**	**81,359**

Business combinations

On 21 June 2022 we acquired, in an all-cash transaction, 100% of the shares and voting interests of CellPoint for a total agreed payment at completion of €125 million, including consideration for other liabilities associated with the transaction amounting to €10.3 million. Additional contingent consideration up to €100.0 million is due when certain development, regulatory and sales-based milestones would be achieved.

On the same date we acquired all of the outstanding capital of AboundBio, for a total agreed price of $14 million, including consideration for other liabilities associated with the transaction.

The main reason for these acquisitions is to position ourselves in next-generation cancer therapy market and to significantly broaden our portfolio and capabilities. As a result of these acquisitions, we gain access to an innovative, scalable, decentralized and automated point-of-care cell therapy supply model as well as a next-generation fully human antibody-based therapeutics platform. Combined and supported by us as a fully integrated biopharma, they have the potential to disrupt the CAR-T treatment paradigm. The goal is to expand the current market for CAR-T therapies and have an important impact on patients in need of additional and improved treatment options.

Details of the preliminary fair value of identifiable assets and liabilities acquired in both transactions, the preliminary purchase consideration and provisional goodwill at the acquisition date are as follows:

	21 June 2022		
(thousands of €)	CellPoint	AboundBio	Total
Property, plant and equipment	1,289	965	
Other non-current assets	81	4	
Trade and other receivables	162	-	
Cash and cash equivalents	3,179	4,279	
Other current assets	1,254	536	
Trade and other liabilities	(32,789)	(587)	
Current deferred income	-	(474)	
Net assets acquired	**(26,824)**	**4,723**	
Consideration paid in cash	107,750	14,886	
Fair value re-measurement of previously held equity investment	-	342	
Deferred consideration	6,088	90	
Fair value of contingent consideration	22,865	-	
Fair value of total consideration	**136,703**	**15,318**	
Goodwill	**163,526**	**10,595**	
Exchange differences on goodwill	**-**	**166**	
Goodwill in the balance sheet	**163,526**	**10,761**	**174,288**

Net cash outflow arising on acquisition

	21 June 2022		
(thousands of €)	CellPoint	AboundBio	Total
Consideration paid in cash	107,750	14,886	
Less: cash and cash equivalents balances acquired	(3,179)	(4,279)	
Cash out from acquisition of subsidiaries, net of cash acquired	**104,571**	**10,607**	**115,178**
Cash used in operating activities for other liabilities related to the acquisition of subsidiaries	**7,765**	**-**	**7,765**

The preliminary fair value of the identifiable assets and liabilities are included in our condensed consolidated interim financial statements as per 30 June 2022. To date we have performed a preliminary fair value analysis of the business combinations, with corresponding adjustments to the trade and other liabilities. We expect the provisional amount of goodwill to change significantly upon the completion of the purchase price allocation, resulting from the valuation of the different assets and liabilities acquired, including the valuation of in-process R&D.

Contingencies and commitments

Contractual obligations and commitments

We have certain purchase commitments principally with CRO subcontractors and certain collaboration partners.

On 30 June 2022, we had outstanding obligations for purchase commitments, which become due as follows:

(thousands of €)	Total	Less than 1 year	1 - 3 years	3 - 5 years	More than 5 years
Purchase commitments	**442,874**	231,179	141,707	46,564	23,425

In addition to the table above, we have a contractual cost sharing obligation related to our collaboration agreement with Gilead for filgotinib. The contractual cost sharing commitment amounted to €304.2 million at 30 June 2022 for which we have direct purchase commitments of €227.4 million at 30 June 2022 reflected in the table above.

Contingent liabilities and assets

We refer to our Annual Report 2021 for a description of our contingent liabilities and assets.

Related party transactions

On 26 January 2022, our current CEO was offered 1,000,000 subscription rights under Subscription Right Plan 2022 (B), which have been accepted on 24 March 2022. The number of accepted subscription rights under Subscription Right Plan 2022 (B) was enacted by notary deed on 25 March 2022. The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €50. Each subscription right gives the right to subscribe for one new Galapagos share. The subscription rights can in principle not be exercised prior to 1 January 2026.

On 3 May 2022, members of the executive committee were offered new restricted stock units ('RSUs'), subject to acceptance. The RSUs are offered for no consideration. Four members of the executive committee accepted all RSUs offered to them. Each RSU represents the right to receive, at Galapagos' discretion, one Galapagos share or a payment in cash of an amount equivalent to the volume-weighted average price of the Galapagos share on Euronext Brussels over the 30-calendar day period preceding the relevant vesting date. The first RSU grant will vest in full three years after the offer date. The second RSU grant has a four-year vesting period, with 25% vesting each year and a first vesting date on 1 May 2023. For the members of the executive committee, any vesting prior to the third anniversary of the offer date will always give rise to a payment in cash rather than a delivery of shares.

On 6 May 2022, members of the executive committee were offered new subscription rights under Subscription Right Plan 2022 BE, subject to acceptance. A first portion of the number of accepted subscription rights under Subscription Right Plan 2022 BE was enacted by notary deed on 7 July 2022. For three members of the executive committee, the suspensive condition of acceptance is still outstanding. The subscription rights have an exercise term of eight years as of the date of the offer. The exercise price of the subscription rights is €57.46 (the closing price of the Galapagos share on Euronext Amsterdam and Brussels on the day preceding the date of the offer). Each subscription right gives the right to subscribe for one new Galapagos share. For all the beneficiaries under Subscription Right Plan 2022 BE the subscription rights vest only and fully on the first day of the fourth calendar year following the calendar year in which the grant was made. The subscription rights are not transferable and can in principle not be exercised prior to 1 January 2026.

The table below sets forth the number of subscription rights offered under Subscription Right Plan 2022 (B) and Subscription Right Plan 2022 BE and the total number of RSUs accepted by each member of the executive committee during the first six months of 2022:

Name	Title	Number of 2022 subscription rights offered	Number of 2022 RSUs accepted
Stoffels IMC BV [1]	CEO	1,000,000 [2]	74,408
Bart Filius	President, CFO & COO	68,000 [3]	61,442
Walid Abi-Saab	CMO	32,000	37,274
Michele Manto	CCO	24,000	27,354

[1] Stoffels IMC BV (permanently presented by Dr. Paul Stoffels).
[2] These subscription rights have already been accepted.
[3] 100 subscription rights have already been accepted, the remainder is outstanding for acceptance.

On 26 April 2022, Galapagos held an extraordinary shareholders' meeting, followed by its annual shareholders' meeting. All agenda items were approved, including the approval of (a) the appointment of Stoffels IMC BV (permanently represented by Dr. Paul Stoffels) as director, and (b) the appointments of Jérôme Contamine and Dr. Dan Baker as independent directors within the meaning of article 7:87 of the Belgian Companies and Associations Code and article 3.5 of the Belgian Corporate Governance Code 2020. Subsequently, the (new) unitary board has appointed Stoffels IMC BV (permanently represented by Dr. Paul Stoffels) as chair of the board of directors.

The mandates of Howard Rowe and Katrine Bosley as members of the board of directors came to an end on 26 April 2022.

During the first six months of 2022, other than as disclosed in the paragraph above, there were no changes to related party transactions disclosed in the 2021 annual report that potentially had a material impact on the financials of Galapagos of the first six months of 2022.

Events after the end of the reporting period

There were no adjusting events nor material non-adjusting events to be reported.

Glossary

100 points clinical response

Percentage of patients achieving a 100-point decrease in CDAI score during a clinical trial in CD patients

ACR

American College of Rheumatology

ACR20 (ACR 20/50/70)

American College of Rheumatology 20% response rate signifies a 20% or greater improvement in the number of swollen and tender joints as well as a 20% or greater improvement in three out of five other disease-activity measures. ACR50 and ACR70 reflect the same, for 50% and 70% response rates, respectively

ADPKD

Autosomal dominant polycystic kidney disease, a disease where typically both kidneys become enlarged with fluid-filled cysts, leading to kidney failure. Other organs may be affected as well

ADS

American Depositary Share; Galapagos has a Level 3 ADS listed on Nasdaq with ticker symbol GLPG and CUSIP number 36315X101. One ADS is equivalent to one ordinary share in Galapagos NV

AFM

Dutch Authority for the Financial Markets

Anemia

Condition in which the patient has an inadequate number of red blood cells to carry oxygen to the body's tissues

Anti-TNF

Tumor necrosis factor. An anti-TNF drug acts by modulation of TNF

Antibody

A blood protein produced in response to and counteracting a specific antigen. Antibodies combine chemically with substances which the body recognizes as alien, such as bacteria, viruses, and foreign substances

Assays

Laboratory tests to determine characteristics

Attrition rate

The historical success rate for drug discovery and development, based on publicly known development paths. Statistically seen, investment in at least 12 target-based programs is required to ensure that at least one of these will reach a Phase 3 study. Most new drug R&D programs are discontinued before reaching Phase 3 because they are not successful enough to be approved

BID dosing

Twice-daily dosing (bis in die)

Bioavailability

Assessment of the amount of product candidate that reaches a body's systemic circulation after (oral) administration

Biomarker

Substance used as an indicator of a biological process, particularly to determine whether a product candidate has a biological effect

Bispecific antibody

An antibody that binds to two different antigens

Black & Scholes model

A mathematical description of financial markets and derivative investment instruments that is widely used in the pricing of European options and subscription rights

Bridging trial

Clinical trial performed to "bridge" or extrapolate one dataset to that for another situation, i.e. to extrapolate data from one population to another for the same drug candidate, or to move from IV to subcutaneous dosing

CAR-T

Chimeric antigen receptor T cells (also known as CAR T cells) are T cells that have been genetically engineered to produce an artificial T cell receptor for use in immunotherapy

CD19

CD19 is a protein found on the surface of B-cells, a type of white blood cell. Since CD19 is a hallmark of B-cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B-cell lymphomas

CDAI

Crohn's Disease Activity Index, evaluating patients on eight different factors, each of which has a pre-defined weight as a way to quantify the impact of CD

CDAI remission

In the FITZROY trial, the percentage of patients with CD who showed a reduction of CDAI score to <150

CFTR

Cystic fibrosis transmembrane conductance regulator (CFTR) is a membrane protein and chloride channel in vertebrates that is encoded by the CFTR gene. It is hypothesized that inhibition of the CFTR channel might reduce cyst growth and enlargement for patients with ADPKD. GLPG2737 is a CFTR inhibitor

CHIT1/AMCase

Chitotriosidase (CHIT1) is a protein coding gene, and AMCase is an inactive acidic mamalian chitinase. CHIT1 is predominantly involved in macrophage activation. Inhibition of chitinase activity translates into a potential therapeutic benefit in lung diseases like IPF, as shown in preclinical models. GLPG4716 is a CHIT1/AMCase inhibitor targeting a key pathway in tissue remodeling

CHMP

Committee for Medicinal Products for Human Use is the European Medicines Agency's (EMA) committee responsible for human medicines and plays a vital role in the authorization of medicines in the European Union (EU)

CIR

Crédit d'Impôt Recherche, or research credit. Under the CIR, the French government refunds up to 30% of the annual investment in French R&D operations, over a period of three years. Galapagos benefits from the CIR through its operations in Romainville, just outside Paris

CRP

C-reactive protein is a protein found in the blood, the levels of which rise in response to inflammation

Cash position

Current financial investments and cash and cash equivalents

Chitinase

Chitinase is an enzyme that degrades chitin, involved in the human innate immunity. Inhibition of chitinase activity translates into a potential therapeutic benefit in lung diseases like IPF, as shown in preclinical models

Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia is the most common leukemia in adults. It is a type of cancer that starts in cells that become certain white blood cells (called lymphocytes) in the bone marrow. The cancer (leukemia) cells originate in the bone marrow and migrate to the bloodstream

Clinical Proof of Concept (PoC)

Point in the drug development process where the product candidate first shows efficacy in a therapeutic setting

Complete Response Letter (CRL)

A letter send by the FDA to indicate that the review cycle for an application is complete and the application is not ready for approval in its present form

Compound

A chemical substance, often a small molecule with drug-like properties

Contract research organization (CRO)

Organization which provides drug discovery and development services to the pharmaceutical, biotechnology and medical devices industry on a contract basis

Corticosteroids

Any of a group of steroid hormones produced in the adrenal cortex or made synthetically. They have various metabolic functions and some are used to treat inflammation

Crohn's disease (CD)

An IBD involving inflammation of the small and large intestines, leading to pain, bleeding, and ultimately in some cases surgical removal of parts of the bowel

Cytokine

A category of small proteins which play important roles in signaling in processes in the body

DARWIN

Phase 2 program for filgotinib in RA. DARWIN 1 explored three doses, in twice-daily and once-daily administration, for up to 24 weeks in RA patients with insufficient response to methotrexate (MTX) and who remained on their stable background treatment with MTX. DARWIN 2 explored three once-daily doses for up to 24 weeks in RA patients with insufficient response to methotrexate (MTX) and who washed out of their treatment with MTX. DARWIN 1 and 2 were double-blind, placebo-controlled trials which recruited approximately 900 patients globally and for which results were reported in 2015. DARWIN 3 is a long term extension trial in which all patients are on 200 mg filgotinib, except for U.S. males who are on 100 mg. The week 156 results from DARWIN 3 were reported in 2019

DAS28 (CRP)

DAS28 is an RA Disease Activity Score based on a calculation that uses tender and swollen joint counts of 28 defined joints, the physician's global health assessment and a serum marker for inflammation, such as C- reactive protein. DAS28 (CRP) includes the C-reactive protein score calculation: scores range from 2.0 to 10.0, with scores below 2.6 being considered remission

DDI study

Drug-drug interaction study. This type of study will assess if there is a change in the action or side effects of a drug caused by concomitant administration with another drug

DIVERGENCE

Phase 2 programs with filgotinib in Crohn's disease. DIVERGENCE 1 was an exploratory study in small bowel CD and DIVERGENCE 2 in fistulizing CD

DIVERSITY

Phase 3 program evaluating filgotinib in CD

DMARDs

Disease modifying anti rheumatic drugs; these drugs address the disease itself rather than just the symptoms

Deep venous thrombosis (DVT)

The formation of one or more blood clots in one of the body's large veins, most commonly in the lower limbs. The blood clots can travel to the lung and cause a pulmonary embolism

Degradation

The process by which proteins are lost through the use of drugs such as PROTACs or small molecules

Dermatomyositis

Dermatomyositis is a rare inflammatory disease. Common symptoms include distinctive skin rash, and inflammatory myopathy, or inflamed muscles, causing muscle weakness

Development

All activities required to bring a new drug to the market. This includes preclinical and clinical development research, chemical and pharmaceutical development and regulatory filings of product candidates

Discovery

Process by which new medicines are discovered and/or designed. At Galapagos, this is the department that oversees target and drug discovery research through to nomination of preclinical candidates

Disease-modifying

Addresses the disease itself, modifying the disease progression, not just the symptoms of the disease

Dose-range finding study

Phase 2 clinical study exploring the balance between efficacy and safety among various doses of treatment in patients. Results are used to determine doses for later studies

Double-blind

Term to characterize a clinical trial in which neither the physician nor the patient knows if the patient is taking placebo or the treatment being evaluated

EC

European Commission

EMA

European Medicines Agency, in charge of European market authorization of new medications

Efficacy

Effectiveness for intended use

End-to-end

A process that takes a system or service from beginning to end and delivers a complete functional solution, usually without strong reliance on third parties

Endoscopy

A non-surgical procedure involving use of an endoscope to examine a person's digestive tract

FDA

The U.S. Food and Drug Administration is an agency responsible for protecting and promoting public health and in charge of American market approval of new medications

FIH

First-in-human clinical trial, usually conducted in healthy volunteers with the aim to assess the safety, tolerability and pharmacokinetics of the product candidate

FILOSOPHY

Phase 4 program evaluating filgotinib in RA

FINCH

Phase 3 program evaluating filgotinib in RA

FITZROY

A double-blind, placebo controlled Phase 2 trial with filgotinib in 177 CD patients for up to 20 weeks. Full results were published in The Lancet in 2016

FORM 20-F

Form 20-F is an SEC filing submitted to the US Securities and Exchange Commission

FSMA

The Belgian market authority: Financial Services and Markets Authority, or Autoriteit voor Financiële Diensten en Markten

FTE

Full-time equivalent; a way to measure an employee's involvement in a project. For example, an FTE of 1.0 means that the equivalent work of one full-time worker was used on the project

Fast Track

A designation by the FDA of an investigational drug for expedited review to facilitate development of drugs which treat a serious or life-threatening condition and fill an unmet medical need

Fee-for-service

Payment system where the service provider is paid a specific amount for each procedure or service performed

Filgotinib

Formerly known as GLPG0634, commercial name is Jyseleca. Small molecule preferential JAK1 inhibitor, approved in RA in European Union, Great Britain, and Japan, and in UC in European Union and Great Britain. Application for approval for ulcerative colitis was filed in Japan. Filgotinib is partnered with Gilead. Filgotinib currently is in Phase 3 trials in CD, and in a Phase 4 trial in RA

Fistulizing CD

Fistulae are inflammatory tracts that most often occur between the distal colon and the perianal region. Fistulae are one of the most severe sequelae of luminal CD and the lifetime risk of occurrence is close to 50% of those with active CD

Futility analysis

Analysis of the likelihood of a trial to meet its primary endpoint, based on a subset of the total information to be gathered. The term 'futility' is used to refer to the low likelihood of a clinical trial to achieve its objectives. In particular, stopping a clinical trial when the interim results suggest that it is unlikely to achieve statistical significance can save resources that could be used on more promising research

G&A expenses

General & administrative expenses

GLIDER

Phase 2 Proof of Concept trial with SIK2/3 inhibitor GLPG3970 in Sjögren's syndrome

GLPG0555

A JAK1 inhibitor in Phase 1b. Development was stopped in July 2022

GLPG0634

Molecule number currently known as filgotinib and Jyseleca

GLPG2737

A compound currently in Phase 2 in ADPKD. This compound is part of the CF collaboration with AbbVie but Galapagos retained rights outside of CF

GLPG3121

A compound in Phase 1 targeting JAK1/TYK2 directed toward inflammation (IBD). Development was stopped in July 2022

GLPG3667

A TYK2 kinase inhibitor discovered by us, topline results from the Phase 1b in psoriasis reported in July 2021

GLPG3970

A SIK2/3 inhibitor in multiple Phase 2 Proof of Concept studies. Topline results from the studies in UC, psoriasis and RA were reported in July 2021. The compound was discontinued in March 2022

GLPG4399

A SIK3 inhibitor currently in Phase 1 directed toward inflammation

GLPG4586

A compound with undisclosed mode of action in preclinical phase directed toward fibrosis and inlicensed from Fibrocor. The development was stopped in July 2022

GLPG4605

A SIK2/3 inhibitor in the preclinical phase, currently directed toward fibrosis

GLPG4716

A chitinase inhibitor inlicensed from Molecure (previously OncoArendi). The rights to the molecule have been returned to Molecure in July 2022

Genome

An organism's complete set of genetic information needed to build that organism and allow it to grow and develop

HDL

High-density lipoprotein. HDL scavenges and reduces low-density lipoprotein (LDL) which contributes to heart disease at high levels. High levels of HDL reduce the risk for heart disease, while low levels of HDL increase the risk of heart disease

Hemoglobin

A protein inside red blood cells that carries oxygen from the lungs to tissues and organs in the body and carries carbon dioxide back to the lungs

Histology

Study of the microscopic structures of tissues

Histopathology

Microscopic examination of tissues for manifestations of a disease

IBD

Inflammatory Bowel Disease. This is a general term for an autoimmune disease affecting the bowel, including CD and UC. CD affects the small and large intestine, while UC affects the large intestine. Both diseases involve inflammation of the intestinal wall, leading to pain, bleeding, and ultimately, in some cases, surgical removal of part of the bowel

IPF

Idiopathic pulmonary fibrosis. A chronic and ultimately fatal disease characterized by a progressive decline in lung function. Pulmonary fibrosis involves scarring of lung tissue and is the cause of shortness of breath. Fibrosis is usually associated with a poor prognosis. The term "idiopathic" is used because the cause of pulmonary fibrosis is still unknown

In vitro

Studies performed with cells outside their natural context, for example in a laboratory

In vivo

Studies performed with animals in a laboratory setting

In-/out-licensing

Receiving/granting permission from/to another company or institution to use a brand name, patent, or other proprietary right, in exchange for a fee and/or royalty

Inflammatory diseases

A large, unrelated group of disorders associated with abnormalities in inflammation

Intellectual property

Creations of the mind that have commercial value and are protected or protectable, including by patents, trademarks or copyrights

Intersegment

Occurring between the different operations of a company

Investigational New Drug (IND) Application

United States Federal law requires a pharmaceutical company to obtain an exemption to ship an experimental drug across state lines, usually to clinical investigators, before a marketing application for the drug has been approved. The IND is the means by which the sponsor obtains this exemption, allowing them to perform clinical studies

JAK

Janus kinases (JAK) are critical components of signaling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in RA. Filgotinib is a preferential JAK1 inhibitor

Jyseleca®

Jyseleca® is the brand name for filgotinib

LDL

Low-density lipoprotein. LDL contributes to heart disease at high levels

Lipoprotein

Lipoproteins are substances made of protein and fat that carry cholesterol through your bloodstream. There are two main types of cholesterol: High-density lipoprotein (HDL), or "good" cholesterol and Low-density lipoprotein (LDL), or "bad" cholesterol

Liver enzymes

Inflamed or injured liver cells secrete higher than normal amounts of certain chemicals, including liver enzymes, into the bloodstream

Lymphocyte

Type of white blood cell that is part of the immune system

MACE

Major adverse cardiovascular events; a composite endpoint frequently used in cardiovascular research

MANGROVE

Phase 2 program with GLPG2737 in autosomal dominant polycystic kidney disease

MANTA

A Phase 2 semen parameter trial with filgotinib in male patients with CD or UC

MANTA-RAy

Phase 2 semen parameter trial with filgotinib in male patients with RA, PsA, or AS

MHLW

Japanese Ministry of Health, Labor and Welfare (MHLW), in charge of Japanese market authorization of new medications

MHRA

Medicines and Healthcare products Regulatory Agency in Great Britain

MTX

Methotrexate; a first-line therapy for inflammatory diseases

Mayo Score

Mayo Score is a Disease Activity Score for ulcerative colitis. It is a composite of subscores from four categories, including stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy or colonoscopy, and physician's global assessment, with a total score ranging from 0–12

Milestone

Major achievement in a project or program; in our alliances, this is usually associated with a payment

Modulation

The process by which the function of proteins is changed through the use of drugs such as small molecules, peptides, antibodies or cell therapy

Molecule collections

Chemical libraries, usually consisting of drug-like small molecules that are designed to interact with specific target classes. These collections can be screened against a target to generate initial "hits" in a drug discovery program

NDA

New Drug Application

NICE

The National Institute for Health and Care Excellence; an independent public body that provides national guidance and advice to improve health and social care in the UK

NK cells

Natural killer cells, type of white blood cell with granules of enzymes which can attack tumors or viruses

Neutrophil

Type of immune system cell which is one of the first cell types to travel to the site of an infection in the body. Neutrophils are another type of white blood cell which fight infection by ingesting and killing microorganisms

Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin lymphoma is a type of cancer that begins in the lymphatic system, which is part of the body's germ-fighting immune system. In non-Hodgkin lymphoma, white blood cells called lymphocytes grow abnormally and form tumors throughout the body

Oligonucleotide

Short DNA or RNA molecule that can be used as research tools or therapeutic drug to change protein expression

Oral dosing

Administration of medicine by the mouth, either as a solution or solid (capsule, pill) form

Osteoarthritis (OA)

The most common form of arthritis, usually occurring after middle age, marked by chronic breakdown of cartilage in the joints leading to pain, stiffness, and swelling

Outsourcing

Contracting work to a third party

PASI

Psoriasis Area and Severity Index; an index used to express the severity of psoriasis. It combines the severity (erythema, induration and desquamation) and percentage of affected area

PRAC

Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, responsible for assessing all aspects of risk management of human medicines

PROTAC

Proteolysis targeting chimera, a special small molecule capable of removing unwanted proteins that play a role in disease processes

Pharmacokinetics (PK)

Study of what a body does to a drug; the fate of a substance delivered to a body. This includes absorption, distribution to the tissues, metabolism and excretion. These processes determine the blood concentration of the drug and its metabolite(s) as a function of time from dosing

Phase 1

First stage of clinical testing of an investigational drug designed to assess the safety and tolerability, pharmacokinetics of a drug, usually performed in a small number of healthy human volunteers

Phase 2

Second stage of clinical testing, usually performed in no more than several hundred patients, in order to determine efficacy, tolerability and the dose to use

Phase 3

Large clinical trials, usually conducted in several hundred to several thousand patients to gain a definitive understanding of the efficacy and tolerability of the candidate treatment; serves as the principal basis for regulatory approval and access to the market

Phenotypic screening

Phenotypic screening is a strategy used in drug discovery to identify molecules with the ability to alter a cell's disease characteristics. Animal models and cell-based assays are both strategies used to identify these molecules. In contrast to target-based drug discovery, phenotypic screening does not rely on knowing the identity of the specific drug target or its hypothetical role in the disease. A key benefit this approach has over target-based screening, is its capacity to capture complex biological mechanisms that are not otherwise achievable

Pivotal trials

Registrational clinical trials

Placebo

A substance having no pharmacological effect but administered as a control in testing a biologically active preparation

Point-of-care

Drug treatment is provided close to or near the patient

Preclinical

Stage of drug research development, undertaken prior to the administration of the drug to humans. Consists of *in vitro* and *in vivo* screening, pharmacokinetics, toxicology, and chemical upscaling

Preclinical candidate (PCC)

A new molecule and potential drug that meets chemical and biological criteria to begin the development process

Product candidate

Substance that has satisfied the requirements of early preclinical testing and has been selected for development, starting with formal preclinical safety evaluation followed by clinical testing for the treatment of a certain disorder in humans

Proof of Concept (POC)

A clinical trial in which first evidence for efficacy of a candidate drug is gathered. A Proof of Concept trial is usually with a small number of patients and for short duration to get a first impression of drug activity

Proof of Concept study

Phase 2 patient study in which activity as well as safety in patients is evaluated, usually for a new mechanism of action

Pulmonary embolism

A blockage in one of the pulmonary arteries in the lungs

QD dosing

Once-daily dosing (qd from the Latin quaque die)

R&D operations

Research and development operations; unit responsible for discovery and developing new product candidates for internal pipeline or as part of risk/reward sharing alliances with partners

Refractory

"Refractory" refers to a patient with cancer that is/has become resistant to, or does not respond to, treatment

Relapsed

"Relapsed" refers to a patient with cancer that develops cancer again after a period of improvement

Replication

The process by which DNA is copied to produce two identical DNA molecules during the process of cell division

Rheumatoid arthritis (RA)

A chronic, systemic inflammatory disease that causes joint inflammation, and usually leads to cartilage destruction, bone erosion and disability

S&M expenses

Sales and marketing expenses

SEC

Securities and Exchange Commission in the US

SELECTION

Phase 3 program evaluating filgotinib in UC patients. Full results were published in The Lancet in 2021

SES-CD scores

Simple endoscopic score for CD, involving review of five pre-defined bowel segments, assigning values from 0 (unaffected) to 3 (highly affected)

SIK

Salt-inducible kinase. This is the target family for the portfolio of molecules in the Toledo program

Screening

Method usually applied at the beginning of a drug discovery campaign, where a target is tested in a biochemical assay against a series of small molecules or antibodies to obtain an initial set of "hits" that show activity against the target. These hits are then further tested or optimized

Short interfering RNA

A research tool that is used to silence the activity of specific genes

Sjögrens syndrome

Sjögren's Syndrome is a systemic inflammatory disease which can be felt throughout the body, often resulting in chronic dryness of the eyes and mouth

Small bowel CD (SBCD)

CD causes chronic inflammation and erosion of the intestines. It can affect different regions of gastrointestinal tract including the stomach and small and large intestines. While isolated SBCD is an uncommon presentation of CD, involvement of some portion of the small bowel, particularly the ileum, is common

Statin

Statins are a class of lipid-lowering medications that reduce illness and mortality in those who are at high risk of cardiovascular disease. They are the most common cholesterol-lowering drugs. Low-density lipoprotein (LDL) carriers of cholesterol play a key role in the development of atherosclerosis and coronary heart disease via the mechanisms described by the lipid hypothesis

Systemic lupus erythematosus

An autoimmune disease, with systemic manifestations including skin rash, erosion of joints or even kidney failure

TEAE

Treatment Emergent Adverse Event, is any event not present prior to the initiation of the treatments or any event already present that worsens in either intensity or frequency following exposure to the treatments

TYK

Tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to the tyrosine residues of specific proteins inside a cell. It functions as an "on" or "off" switch in many cellular functions. Tyrosine kinases belong to a larger class of enzymes known as protein kinases which also attach phosphates to other amino acids such as serine and threonine. GLPG3667 is a reversible and selective TYK2 kinase domain inhibitor

Target

Proteïn that has been shown to play a role in a disease process and that forms the basis of a therapeutic intervention or discovery of a medicine

Target discovery

Identification and validation of proteins that have been shown to play a role in a disease process

Technology access fee

License payment made in return for access to specific technology (e.g. compound or virus collections)

Toledo

Toledo is the program name for the target family of SIK inhibitors

Topical corticosteroids

Corticosteroids which are administered through the skin using an ointment

Transcription

The process of making an RNA copy of a DNA gene sequence

Translation

The process by which a protein is synthetized from mRNA

Ulcerative colitis (UC)

UC is an IBD causing chronic inflammation of the lining of the colon and rectum (unlike CD with inflammation throughout the gastrointestinal tract)

Venous thrombotic events

When a blood clot breaks loose and travels in the blood, this is called a venous thromboembolism (VTE). The abbreviation DVT/PE refers to a VTE where a deep vein thrombosis (DVT) has moved to the lungs (PE or pulmonary embolism)

Financial calendar

03 November 2022

Third quarter 2022 results

23 February 2023

Full year 2022 results

Colophon

Concept, design and online programming
nexxar GmbH, Vienna – Online annual reports and online sustainability reports
www.nexxar.com

Photography
Frank van Delft

Copy deadline: 4 August 2022

This report is also available in Dutch and available for download in the **Downloads** section of this report or at **www.glpg.com**

Contact

Sofie Van Gijsel
Head of Investor Relations
Galapagos NV
Generaal De Wittelaan L11 A3
2800 Mechelen, Belgium
Tel. +1 781 296 1143
Email: ir@glpg.com

Sandra Cauwenberghs
Director of Investor Relations
Galapagos NV
Generaal De Wittelaan L11 A3
2800 Mechelen, Belgium
Tel. +32 15 34 29 00
Email: ir@glpg.com

Marieke Vermeersch
Head of Corporate Communication
Galapagos NV
Generaal De Wittelaan L11 A3
2800 Mechelen, Belgium
Tel. +32 479 49 06 03
Email: media@glpg.com